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ABSTRACT 
 
Oral lichen planus (OLP) is a chronic inflammatory disease of unknown etiology. 
Typical management of OLP involves topical corticosteroids. Recent literature shows an 
association between high levels of various oxidative stress markers, such as 
malondialdehyde (MDA), and OLP. A combination antioxidant gel consisting of 
phloretin and ferulic acid has been shown to have beneficial effects. In order to test the 
efficacy of this particular combination of antioxidants in managing OLP and to 
contribute to the literature linking oxidative stress to signs and symptoms of OLP, we 
conducted a double-blinded, placebo-controlled randomized clinical trial. A total of 33 
patients with biopsy-confirmed OLP being treated for at least 6 weeks and presenting 
with persistent or non-responsive symptoms and lesions were given either a placebo 
(PLC, n = 16) or a test gel (AO, n = 17) and instructed to use three times a day for 4 
weeks. Symptom scoring using a VAS, lesional scoring using an OLP scoring system, 
and salivary levels of oxidative stress markers, 8-hydroxy-deoxyguanosine (8-OH-dG) 
and malondialdehyde (MDA) were measured at baseline, 2 weeks, and 4 weeks. 
VAS for the AO group decreased to 14.25 ± 14.05 at 2 weeks and 16.75 ± 22.14 
at 4 weeks from 33.25 ± 28.82 at baseline, OLP lesional scores decreased to 6.26 ± 4.10 
at 2 weeks and was 6.53 ± 4.63 at 4 weeks from 7.79 ± 5.18 at baseline, 8-OH-dG 
decreased 17.9% from 216.88 ± 132.01 at baseline to 178 ± 116.56 at 4 weeks, and 
MDA increased from 3.24 ± 1.07 to 4.63 ± 1.82 at 4 weeks. The changes were not 
statistically different from the PLC group in terms of VAS, OLP lesion score, salivary 8-
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OH-dG, and salivary MDA at any time point (p >0.05) except for at 4 weeks for MDA 
(p <0.05. The study revealed that a topical combination antioxidant gel did not differ 
from a placebo in any of the parameters measured. However, patients did not report any 
severe flare-ups and had better patient acceptance to topical steroids. To our knowledge, 
this is the first study to report on salivary 8-OH-dG and MDA levels in patients with oral 
lichen planus undergoing treatment. 
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 INTRODUCTION AND LITERATURE REVIEW 
 
Oral Lichen Planus 
Definitions and Demographics 
Lichen planus (LP) is a disorder of T-cell-mediated chronic inflammation of 
stratified squamous epithelium.  First described by Erasmus Wilson in 1869, it has a 
wide range of clinical manifestations with oral lichen planus (OLP) being the second 
most common manifestation after cutaneous lichen planus. About 1-2% of the general 
adult population has OLP and 35% of patients with LP have oral lesions exclusively.1 
McCartan & Healy reported an overall prevalence of 1.5% in the general population and 
a 2.3% prevalence in women.2 OLP affects women more than men at a ratio of 
approximately 1.4:1 in some studies.3 OLP occurs predominantly in adults over 401 
although younger adults and children may be affected.4 
Clinical Presentations 
LP manifests in a variety of clinical forms. Concomitant skin lesions occur in 
about 15% of patients5 and typically present as purple, flat-topped papules about 2-4 mm 
in diameter on the wrist, ankles, and genitalia.  Involvement of nails results in pitting, 
pterygium formation, and permanent nail loss.  Occasional scalp involvement leads to 
alopecia, which is termed lichen planus planopilaris or Graham-Little syndrome.6 
 Intraorally, OLP can manifest anywhere in the mouth, but is most commonly 
found on the buccal mucosa followed by the tongue, gingiva, labial mucosa, and 
vermillion border of the lower lip.7 Scully and El-Kom reported that roughly 10% of 
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patients have OLP confined to the gingiva,6 Eisen reported that 8.6% of patients had 
gingival OLP,8 and Mignogna reported the prevalence of gingival OLP to be 7.4%.9  
Lesions can be either unilateral or bilateral, but most report bilateral involvement.6 
 There are 6 clinical variants: reticular, papular, plaque-like, erosive (ulcerative), 
atrophic (erythematous) and bullous.10  The reticular form is the most common type and 
presents as slightly raised, fine, whitish lines in an interlocking lace-like pattern coined 
“Wickham’s striae.” The striae are often present bilaterally and occur mostly on the 
buccal mucosa and most patients with reticular lesions are asymptomatic.8 The erosive 
form is the second most common type and is often extensive, irregular, and affects 
mainly the lingual and buccal mucosa.  The erosive lesions are usually red and 
involvement of the gingiva usually leads to desquamative gingivitis. Erosive lesions 
usually do not resolve and may make differential diagnosis from other autoimmune 
mucosal diseases difficult.8 The atrophic form presents as a diffuse red lesion, often 
surrounded by white striae around the border of the lesion, and usually appears as a 
mixture of subtypes.7 This lesion frequently manifests with “Nikolsky’s sign” in which 
the epithelium easily sloughs under slight, rubbing pressure. This sloughing frequently 
involves the gingiva which is commonly referred to as a “chronic desquamative 
gingivitis.”11 There appears to be a significant correlation between patients ≥ 60 years of 
age and the presence of atrophic lesions.12 Both the erosive and atrophic forms result in 
pain and a burning sensation.8 The papular form consists of small 0.5-1 mm-wide white, 
raised papules which are easy to overlook. They also usually occur in association with 
another subtype.11 The plaque-like form closely resembles leukoplakia but sometimes 
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presents with reticular borders. The primary sites for the plaque-like form are the dorsum 
of the tongue and the buccal mucosa. Thorn reported that these lesions are often found in 
smokers.12 Finally, the bullous (blister) form is rare and may range from only a few 
millimeters to several centimeters. They are usually surrounded by a reticular border and 
may easily rupture resulting in a painful ulcerated surface.12 
Histology 
 Histological features of OLP were first described by Dubreuill in 190613 and 
subsequently by Shklar.14 Histologically, OLP is characterized by three classic features: 
1) a dense band-like layer of chronic inflammatory infiltrate in the connective tissue 
region, liquefactive degeneration of the basal cell layer of the epithelium, and overlying 
hyperkeratinization in the reticular, papular or plaque-like forms.14 Degenerating basal 
keratinocytes form colloid bodies called Civatte or hyaline bodies which often appear in 
the epithelium or underlying connective tissue. Recent studies have shown that these 
Civatte bodies are comprised of apoptotic keratinocytes. Sometimes cleft formations can 
be seen histologically due to weaknesses at the epithelial-connective tissue interface; this 
clefting is called a Max-Joseph space. Some other elements of OLP include acanthosis 
and the presence of “saw-tooth” rete ridge formations.1 The histological criteria for the 
definitive diagnosis of OLP include liquefactive degeneration of the basal cell layer and 
a dense, band-like inflammatory infiltrate consisting of lymphocytes. Supportive 
findings include: saw-tooth rete ridges, Civatte bodies, and hyperkeratosis.15 
Exclusionary histological criteria include: absence of liquefactive degeneration of the 
basal cell layer; mixed inflammatory infiltrate; atypical cell morphologies suggestive of 
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dysplasia; blunted rete ridges; absence of Civatte bodies and absence of 
hyperkeratinization.16 
 Oral lichenoid reactions have similar histological characteristics to idiopathic 
OLP, and the World Health Organization (WHO) does not differentiate between the two 
since they cannot be further substantiated by clinical findings. Although no reliable 
histological features that can differentiate lichenoid reactions from idiopathic OLP, some 
authors reported that features such as a deeper-laying inflammatory infiltrate, usually 
around vascular structures, and plasma cells and neutrophils in the connective tissue 
infiltrate could help distinguish it from idiopathic OLP.17 In 2003, van der Meij and van 
der Waal proposed a modification to the WHO diagnostic criteria to include OLL, or 
“oral lichenoid lesion,” as a separate entity as well as adding “absence of epithelial 
dysplasia” as a diagnostic criterion for both OLL and OLP.18 
 Immunofluorescence is not necessary for the diagnosis of OLP but sometimes is 
used to differentiate OLP from other diseases, such as mucous membrane pemphigoid 
and pemphigus vulgaris, that show clinical features similar to OLP. Direct 
immunofluorescence (DIF) is used to detect antibodies in the tissues. Studies utilizing 
DIF have shown a linear pattern and intense fluorescence with anti-fibrinogen outlining 
the basement membrane for OLP. Sometimes deposits if IgM, IgA, IgG, and C3 can be 
found in Civatte bodies.19  
Etiopathogenesis 
 It is clear that the degradation of the basal keratinocytes by the activation of T 
lymphocytes leads to the disease signs and symptoms. However, the etiology for the 
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activation of this immune response is still unknown. In order for the T-cells to be 
activated, there must be an antigen that is presented by the MHC class I molecules.  The 
exact antigen responsible for the activation of T-cells is still unknown, but Sugerman et 
al suggest that it is expressed by keratinocytes after some extrinsic event, such as 
exposure to certain drugs, contact allergens, trauma, bacterial or viral invasions, or an 
intrinsically yet-to-be identified agent. The event subsequently triggers T-cell exposure 
to MHC class I molecules.1 A variety of extrinsic factors may induce the onset of signs 
and symptoms. They include dental restorations and drugs such as antimalarials, ACE 
inhibitors, β-blockers, NSAIDs, gold salts, and hypoglycemics. In cases triggered by 
extrinsic factors, the term “oral lichenoid reactions” is preferred although clinical and 
histologic examination would reveal similar features to classic OLP.20 
 Another potential pathogenic agent may be viral infection. Herpes simplex,21 
Epstein-Barr,21, 22 Cytomegalovirus,23, 24 and herpes virus 623, 25 have all been implicated 
in oral manifestations of lichen planus. Lodi et al  reported that the literature is still 
inconclusive as to whether or not these viral agents are actually associated with signs 
and symptoms or if they are simply superimposed upon lesions already present.26 Of 
these viruses, human papilloma virus (HPV) is one of the most studied and strongly 
linked to OLP. Syrjanen et al reported in a systematic review that HPV prevalence 
among patients with OLP ranged from 7.7% to 32.8%.27 Also, it appeared that more 
severe presentations were associated with a higher prevalence of HPV.20 However, 
Syrjanen et al stated that ulcerative OLP lesions increase the susceptibility to HPV 
infections and that the use of steroids for treatment may actually enhance HPV 
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replication.27 Therefore, the direction of influence between HPV and OLP is still 
unclear. 
 Hepatitis C virus (HCV) has garnered considerable interest since prevalence of 
associated HCV infections with OLP range from 2 % to 67.8%20. Several recent meta-
analyses26, 28, 29 found strong correlations between HCV and OLP in distinctly different 
populations. HCV has the ability to infect other cells besides hepatocytes, and the 
constant immune response associated with the chronic presence of the virus may cause 
genetic mutations leading to development of autoimmune issues such as OLP. Another 
possible interaction between HCV and OLP is that gamma-interferon (INF-γ) treatment, 
which is one of the most common treatments for HCV, can cause oral lichenoid 
reactions.28 A unique characteristic sets HCV-associated OLP apart from classic OLP 
and other OLRs. Carrazzo et al found that patients with OLP and HCV have a higher 
frequency of a specific HLA (human leukocyte antigens) class II allele, HLA-DR6, than 
compared to patients with OLP and no HCV infection.30 Although HCV may have the 
strongest case as a contributing etiologic agent to OLP, many questions remain as to 
what extent HCV and other viral infections are involved in the etiopathogenesis of OLP. 
 Heat shock proteins may play a major role in the pathogenesis of OLP. HSPs, 
which are expressed by all cell types, are involved in cell communication, proliferation, 
growth, signal transduction, and apoptosis. Increased HSP expression is a result of some 
form of exogenous insult such as dramatic temperature changes, medications, viruses, 
inadequate nutrition, and certain growth factors. Sugerman et al have suggested that heat 
shock proteins may be auto-antigens since they are highly expressed in the keratinocytes 
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of OLP patients as well as patients with classic autoimmune diseases. HSPs are overly 
expressed in diseases which are associated with chronicity, a preference for female 
patients, mediation via T lymphocytes, and good response to steroidal therapy. Since all 
of these traits also apply to OLP, there may be an argument to classify OLP as an 
autoimmune disease although the autoimmune component seems to be activated after 
epithelial basal cell degeneration.31 
The inflammatory infiltrate in OLP lesions is predominantly composed of T-
cells, the majority of which are activated CD8+ lymphocytes within the epithelium and 
adjacent to damaged basal keratinocytes.  The CD8+ subset of T-cells, called cytotoxic 
T-cells, are responsible for recruitment of other inflammatory cells to the area and for 
the induction of keratinocyte apoptosis.  Keratinocytes contribute to the structure of the 
epithelial basement membrane by secreting collagen IV and laminin V into the basement 
membrane. There is also evidence that keratinocytes require a basement membrane-
derived cell survival signal to prevent the onset of apoptosis.  Therefore, the basement 
membrane is required for keratinocyte survival and vice versa.  Apoptotic keratinocytes 
are not able to perform this function. Hence, keratinocyte apoptosis triggered by CD8+ 
cytotoxic T cells may result in epithelial basement membrane disruption in OLP which 
allows the non-specific T lymphocytes present in the sub-epithelial zone to migrate into 
the epithelium.32 
CD4+ T-cells may also play a role in the apoptosis of keratinocytes. Sugerman et 
al hypothesized that there may be a secondary antigen which complexes with MHC 
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Class II molecules to activate T helper cells. These active T helper cells may then 
“reconfirm” the CD8+ T-cell’s “request” for cytotoxic activity.1 
In addition to the antigen-specific pathways presented above, Zhou et al have 
suggested that several non-specific mechanisms contribute to the breakdown of the 
keratinocytes of the basal layer.32 Matrix metalloproteinases are a family of nearly 20 
zinc-containing proteins which are responsible for the breakdown of connective tissue 
proteins. Each MMP usually has distinct substrates and are regulated by tissue inhibitors 
of metalloproteinase (TIMPs). Zhou et al found that there were higher levels of MMP-9 
and TIMP-1 from OLP lesional T-cell lysates than peripheral T cells from either OLP or 
healthy patients. MMP-9 is also known as gelatinase B and cleaves type IV collagen. 
They also observed that TNF-α stimulation resulted in activation of only the MMP-9 and 
not TIMP-1. Their results suggested that TNF-α released from T-cells in OLP lesions 
may upregulate MMP-9s to degrade the epithelial basement membrane. As stated before, 
this disruption in the basement membrane also deprives the keratinocytes of the 
keratinocyte survival signal, thereby inducing apoptosis of the keratinocytes.33 
Another non-specific mechanism of basal cell degeneration involves 
hyperactivation of mast cells. In two studies, Zhao et al showed that there was greater 
mast cell density as well as a higher percentage of mast cell degranulation in OLP 
lesional cells. Among the mast cell lysates are MMP-9, which was described above, and 
chymase, which is a potent mast cell protease capable of activating MMP-9. Also 
present in mast cell lysate is TNF-α which promotes endothelial adhesion of T 
lymphocytes to the lesional area. Therefore, Zhao et al concluded that the upregulated 
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mast cell degranulation directly, and indirectly through TNF-α mediated recruitment of 
T-cells, causes a local increase in MMP-9.34, 35 
Zhao et al also found that the chemokine RANTES (regulated on activation, 
normal T-cell expressed and secreted) is released by lesional T-cells. RANTES recruits 
and promotes degranulation of mast cells. TNF-α is an activator of RANTES. Since 
TNF-α is also released by RANTES-induced mast cell degranulation, this results in 
cyclic propagation of inflammation and may contribute to the chronicity of OLP.36 
Sugerman et al also suggest a unifying hypothesis on the pathogenesis of OLP 
which integrates both antigen-specific and non-specific mechanisms. He suggests this 
model: the initiation of OLP is by the OLP antigen binding with an MHC Class I 
molecule on keratinocytes. CD8+ cytotoxic T-cells are thus activated, possibly with help 
from Th1 CD4+ cells induced by a currently unknown secondary OLP antigen, and 
secrete TNF-α to begin keratinocyte apoptosis. These T-cells undergo clonal expansion 
and release RANTES to upregulate mast cell presence and degranulation which also 
increases TNF-α levels. Increased TNF-α levels promote further migration of T-cells and 
MMP-9 activation to induce a cyclic inflammatory response. This culminates in the 
apoptosis of the basal keratinocytes.1 It should be reiterated that a specific OLP antigen 
has not been identified. 
Course of Disease 
OLP lesions may be present for years and undergo phases of exacerbation and 
quiescence. Exacerbations are accompanied by pain and often times erosive or atrophic 
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lesions. For gingival lesions, exacerbations may also be attributed to the low-grade 
chronic inflammation caused by dental plaque.37 
The course of OLP has been studied by several authors. Silverman et al treated 
570 patients for a mean period of 5.5 years. 75% of patients were treated with topical 
corticosteroids. They found that of the treated patients, 29% experience complete 
remission and 63% had partial remission. Only 3% experienced spontaneous remission 
without treatment. The rate of malignant transformation was 1.2% and occurred in 7 
patients in a mean time 3.4 years after onset of the OLP.7 
In another similar study conducted years later, Silverman et al treated 214 
patients over the course of 5 years. The results from his study found that OLP was 
mainly found in women and on the buccal mucosa. Spontaneous remission was found 
only in 6.5% of patients. The rate of malignant transformation was 2.3% after a mean of 
7.5 years after onset of OLP. The erosive form was always associated with pain.38 
Bicker also reported rates of spontaneous remission of the various forms of OLP. 
Reticular lichen planus has a remission rate of 41%, plaque-like LP resolves in 7% of 
cases, and atrophic LP resolves in 12% of cases.11 
Thorn et al followed 611 OLP patients in Denmark seen at least once a year 
(twice if the patients had atrophic and/or erosive lesions) for 26 years. Most patients 
presented with reticular lesions (92%) and of these, 28% (26% of the total pool) had 
complete remission by the end of their last examination. One-third of the patients with 
plaque-like lesions, 50% of patients with atrophic lesions, and two-thirds of patients with 
ulcerative lesions experienced complete remission upon final examination. In total 17% 
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(104) of patients experienced complete remission. Their analysis of various factors and 
their association with complete remission found that the presence of plaque-like lesions 
trended towards complete remission. Other factors such as age, sex, presence of systemic 
diseases, medications, smoking, and other clinical forms other than plaque-like lesions at 
initial presentation did not influence the probability of having complete remission.12 
In another study evaluating the course of the disease as well the efficacy of 
topical/systemic corticosteroids, Chainani-Wu et al retrospectively followed 229 patients 
treated for OLP at a tertiary referral center at UCSF from 1996 to 2000. They scored 
signs of the disease based on increasing severity: 1 = reticular, 2 = atrophic and 3 = 
erosive. Symptoms were graded as: 0 = no symptoms, 1 = mild symptoms that do not 
affect quality of life, 2 = moderate symptoms that were bothersome to the patients and 
needed medical attention, and 3 = severe symptoms that significantly interfered with 
quality of life. Treatment at the center consisted of topical corticosteroids such as 0.05% 
fluocinonide gel, 0.05% fluocinonide ointment mixed with equal parts Orabase paste, 
0.05% clobetasol gel, 0.05% clobetasol ointment mixed with equal parts Orabase paste, 
or systemic corticosteroids. In refractory cases or very severe cases, systemic 
corticosteroids were combined with azathioprine. Treatment responses were scored at 
the first week and long term response was measured by subtracting the 1 week follow-up 
score from the last follow-up visit. The average duration of the disease was 76 months. 
The buccal mucosa was the most common site. Follow-up data were available for 163 
patients, of whom 85 (52%) remained constant in their clinical presentation while 21 
(13%) experienced worsened clinical presentation. Only 41 (25%) experienced 
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improvement, and only 8 (5%) of patients experience complete remission. The overall 
oral squamous cell carcinoma transformation rate was 1.7%.4 
Carbone et al investigated the course of OLP in 808 northern Italian patients in a 
retrospective study of data from 1987 to 2004. They included patients with bilateral 
clinical signs of OLP alone or in association with atrophic or erosive lesions, a positive 
biopsy confirming OLP, and an absence of suspicion that the lesions were associated 
with drugs or oral restorations.  They followed the patients and evaluated them for 
clinical improvement, (defined as a transition of observable lesions from red to white) 
exacerbations (defined as changing from asymptomatic to symptomatic or worsening of 
a symptomatic form), changes in the morphology of the lesions, and partial or complete 
remission. Patients were generally seen twice a year, but those undergoing treatment 
were seen every 2 months. Any treatment was done with a mixture of 0.05% clobetasol 
propionate, 3% cyclosporine, and 0.05% fluocinonide. They found that 421 (52.1%) of 
patients did not have any changes in their white lesions. Of these, only 71 were using a 
form of medication for treatment. One hundred ninety-six patients had no changes in 
their red lesions. In total there were only 20 patients (2.47%) that experienced complete 
remission, 13 of whom had white lesions without treatment, and seven from red lesions. 
Forty-nine patients (6%) had exacerbations of their white lesions into atrophic-erosive 
lesions. The results from their study confirmed the chronicity of the disease with only a 
mere 2.47% of patients achieving complete remission. A majority of patients were stable 
(76.6%) and only a handful became worse off (6%). A little over half of the patients who 
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were responsive to therapy showed acute flare-ups at some point in time, again 
highlighting the chronicity of the disease.39 
Malignant Transformation 
In addition to being a chronic, often painful disease, one of the most important 
sequela for patients and clinicians to be aware of is the potential of OLP lesions to 
transform into squamous cell carcinoma. In fact, the WHO categorizes OLP as a 
precancerous condition which is “a generalized state associated with a significant 
increased risk of cancer.” Krutchkoff et al evaluated the literature from 1950 to 1976 to 
assess the risk of malignant transformation by reviewing 223 reported cases. They 
concluded that the data was inconclusive since many follow-up studies did not use the 
same diagnostic criteria for the initial lesion.40 In 1999, van der Meij used the same 
criteria used by Krutchkoff to examine the evidence from 1977-1999. They found that 
only 33 (34%) of the 98 reported cases were acceptable as showing clear evidence of 
malignant transformation of OLP. However, they still lamented the lack of uniformity in 
diagnosis of OLP which contributed to the difficulty in fully assessing risk.18 
Several studies investigating the course of the disease have reported on malignant 
transformation rates. Silverman et al reported 7 out of 570 patients (1.2%),7 Holmstrup 
et al reported 9 out of 611 patients (1.5%),37 Silverman et al reported 5 out of 214 
patients (2.3%),38 Lo Muzio et al reported 14 out of 263 patients (5.3%),41 Carbone et al 
reported 15 of 808 patients (1.86%),39 and Chainani-Wu et al reported 4 out of 154 
(1.7%) patients.4 In a recent meta-analysis, the average malignant transformation rate 
was 1.09%.42 
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 The mechanism of malignant transformation has been studied extensively. One 
possible mechanism may relate to the macrophage migration inhibitory factor (MIF) 
which was shown to stimulate tumor formation.43-45 MIF is released by T-cells of the 
OLP lesion and also acts to block keratinocyte tumor protein p53, an important cell cycle 
regulator known as “protector of the genome”. Impairment of the p53 gene combined 
with the chronic inflammatory state may allow gene mutations to go unchecked within 
OLP lesions. Another player may be TGF-β1 as studies have shown that varying levels 
of TGF-β1 results in different effects on cell growth, differentiation, and tumor 
suppression. These studies imply that low levels of TGF-β1 may cause hypo-
immunosuppression that exacerbates OLP46 but that abnormally high levels may 
suppress antitumor defenses.47 
Treatment 
Corticosteroids 
 Just as the disease manifests itself in various ways, the methods studied to treat 
OLP are also varied. Tyldesley and Harding studied aerosolized betamethasone 
compared to a placebo in 23 OLP patients over the course of 8 weeks treatment. They 
found that most patients taking the betamethasone showed marked improvement at 2 
weeks and further improved to near complete remission at 8 weeks. However, only 2 of 
the placebo patients showed slight improvement at the end of 8 weeks.48 
 Lozada and Silverman examined the efficacy of 0.05% fluocinonide in an 
adhesive (orabase) used topically to treat oral lichen planus in an effort to find a more 
suitable alternative to systemic steroids and their associated side effects. Eighty-nine 
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patients with various forms of vesiculobullous diseases (OLP, EM, MMP, pemphigus 
vulgaris) were studied in two phases. In the first phase, 15 patients with various diseases 
were tested in a double-blind, crossover experiment with a placebo. Patients were 
instructed to use their active or placebo adhesive material 5 to 6 times per day for 2 
weeks with the first gel and then used the other gel for another two weeks. After the 
crossover period, 6 of the OLP patients experienced complete remission and the 
remaining 5 experienced partial remission while all but one of the patients experienced 
no significant remission of lesions.49 
 In another study examining fluocinonide, Voute et al studied and compared the 
visual analog score (VAS) and treatment responses in 20 patients using 0.025% 
fluocinonide to 20 patients using a placebo after 9 weeks. With regard to clinical signs, 4 
patients experienced complete remission and 12 showed good or partial response in the 
fluocinonide group compared to no patients with complete remission and only 6 with 
partial remission in the placebo group. The same trends were found regarding symptoms, 
and both parameters (signs and symptoms) were statistically different between the two 
groups in favor of the test group.50 
Two studies compared the previously mentioned fluocinonide with another 
topical corticosteroid: clobetasol. In the first, Carbone et al compared 0.05% clobetasol 
ointment to 0.05% fluocinonide ointment for a period of 6 months. Twenty-five patients 
in the clobetasol group, 24 in the fluocinonide group, and 11 in the placebo group were 
examined every 2 months and assessed using a VAS and clinical response scores. 
Plasma cortisol levels were measured in half of the patients in the topical steroids groups 
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to ensure safety of the gels. After treatment, all patients in the clobetasol and 90% of 
patients in the fluocinonide group experienced some form of relief. However, only 20% 
of the placebo patients experienced some sort of relief. When the investigators looked at 
the ability of either ointment to completely resolve the lesions, 75% of the clobetasol-
treated lesions achieved complete responses compared to only 25% of the cases treated 
with fluocinonide. At the final follow-up at six months, roughly 50-60% of the patients 
in either group were stable, and none of the plasma samples showed an adverse increase 
in cortisol levels. Another interesting finding was that none of the patients developed 
oral candidiasis from use of either gel since all were given miconazole gel and 0.12% 
chlorhexidine to use prophylactically.51 
 In a second comparison, Lozada-Nur et al evaluated the efficacy of 0.05% 
clobetasol propionate ointment in orabase compared to 0.05% fluocinonide ointment in 
orabase for the treatment of what they termed oral vesiculoerosive diseases (OVED). 
They treated 60 patients with biopsy-confirmed OVED. There were 43 female and 17 
male patients; 35 were diagnosed with OLP, 3 had BMMP, 3 had PV, and 19 patients 
suffered from EM. 50 patients completed the study. The patients were instructed to use 
whichever adhesive they were given three times a day for 14 days. At the end of 14 days, 
they were instructed to discontinue the medication and were re-examined at 28 days. 
Patients who used clobetasol tended to show greater improvement than fluocinonide 
users at 1 week, but the difference was not significant. Clobetasol users also reported 
increased pain reduction compared to fluocinonide users.52 
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 Since clobetasol had been established as having similar or even better response 
than fluocinonide, Carbone et al compared different concentrations of clobetasol in a 
randomized, controlled, double-blind trial to investigate whether the strength mattered. 
Thirty patients were divided into two equal groups which received either 0.025% or 
0.05% clobetasol and instructed to use the gel twice a day for 2 months. Patients 
recorded symptom scores using a VAS from 0 to 10 and clinical lesions were scored 
using the following scale: Score 0: no lesions, Score 1: hyperkeratotic lesions, Score 2: 
atrophic area ≤ 1 cm2, Score 3: atrophic area >1 cm2, Score 4: erosive area ≤ 1 cm2, and 
Score 5: erosive area >1 cm2. At the end of 2 months of therapy, 14 of 15 patients in the 
0.025% group experienced improvement in their symptoms and 13 of 15 patients in the 
0.05% group experienced symptomatic relief. As for clinical assessment, 13 of the 15 
0.025% group patients and 11 of the 15 0.05% group patients experienced clinical 
improvement after 2 months of therapy.  Both parameters were significantly improved 
from baseline measurements, but were not different between either concentrations of 
clobetasol. The authors suggest that an increased dosage of clobetasol may not 
necessarily be better.39 
 Another study by Carbone et al compared long-term results and effects of 
systemic steroids plus topical steroids versus topical steroid alone. Their study looked at 
49 patients with erosive and/or atrophic OLP lesions. The test group (n = 26) received 
systemic corticosteroids (prednisone) in addition to topical steroids. The control group (n 
= 23) received only topical steroids. To assess any adrenal suppression, blood samples 
were taken before and after treatment to measure levels of serum cortisol, glucose, 
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electrolytes, and creatinine. The initial dosage of prednisone was 50 mg/day until 50% of 
the lesion size was reduced. After this point, the dose was tapered to 25 mg/day for 1 
week, 12.5 mg/day for the next week, and ended at 6 mg/day for the last week. Topical 
treatment comprised of 0.05% clobetasol propionate applied twice a day. Miconazole 
rinse was prescribed to prevent candidiasis in both groups. At the end of the 6 month 
follow-up, both the test and control patients experienced significant reduction in signs 
and symptoms. Also, there was no difference between the percentages of patients 
experiencing complete remission of signs and symptoms between either treatment 
modalities. Seven total patients in the test group experience some form of systemic side-
effect such as hypertension, abdominal pain, and water retention, but no other negative 
side-effect of treatment was observed. The authors suggested that high-potency topical 
steroids should remain the treatment of choice and that systemic steroids should be 
reserved for more recalcitrant severe erosive or atrophic cases or cases with diffuse 
systemic involvement.53 
 The efficacy of topical corticosteroids has been very well documented and 
established. They remain the first choice in most clinical situations for the treatment and 
control of OLP. One of the potential drawbacks from the use of corticosteroids, 
especially systemic, may include potential HPA axis suppression, but the literature has 
not supported this as a common risk. Plemons et al studied the levels of urinary and 
serum levels of cortisol to assess whether or not use of topical 0.05% fluocinonide gel 
three times a day for 3 weeks would cause adrenal suppression. Ten patients were given 
fluocinonide to use and another 8 were given a placebo. They found that at day 3 and 21, 
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no differences in cortisol could be detected between the fluocinonide and placebo groups 
and that there was no difference within the subject groups at different time points. They 
suggested that the use of topical steroids does not suppress the HPA axis.54 In fact, none 
of the studies mentioned above reported HPA axis suppression as a side effect of topical 
steroids administered as a gel, ointment, or cream. However, Gonzalez-Miles and Scully 
reported substantial hypothalamus-pituitary-adrenal suppression when aqueous clobetaol 
was used as a rinse 3 times daily.55 
 Another potential side effect is the occurrence of oral candidal infections 
secondary to oral immune suppression. Krogh et al reported that around 37% of OLP 
lesions contain Candida albicans56 and according to several studies, oral candidiasis is a 
common side-effect of topical steroid application. Although Lozada et al reported that 
none of their patients developed symptoms of candidiasis, 3 patients developed 
pseudomembranes.49 Another investigation reported a significant relation between being 
a carrier of candidal species and having candidiasis during the course of treatment. That 
study reported that 18 (35%) were normal carriers and of these, 5 of 8 patients using 
clobetasol and 8 of 10 patients using fluocinonide developed candidiasis during the 
course of treatment.52 Fortunately, the efficacy of using antimycotics during treatment 
with systemic or topical steroids to prevent oral candidiasis was validated by several 
different studies.39, 51, 53  
Cyclosporine 
Alternative avenues of treatment for OLP instead of corticosteroids have been 
widely studied. Among the other popular alternatives is topical cyclosporine. 
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Cyclosporine is a calcineurin inhibitor and acts reversibly to inhibit the effect of immune 
cells during the G0 or G1 phase of the cell cycle. T-cells, mainly T-helper cells, are the 
main target, and cyclosporine also inhibits lymphokine production and the release of IL-
2, a T-cell growth factor. 
 Epstein and Truelove evaluated the benefits of a formulation of cyclosporine 
100mg/ml compounded with Zilactin, which was a topical film comprised of 
hydrocellulose, salicylic, boric, and tannic acids. The study population consisted of 14 
patients with confirmed OLP and patients were instructed to use the gel for 1 month with 
follow-ups at 2 and 4 weeks to assess pain using a VAS and clinical response via area 
measurements of the erosive lesions. At the end of the study, only 8 patients out of 14 
experienced relief, none of whom achieved complete remission, and only 7 patients 
experienced clinical improvement.57 
 Harpenau et al studied the potential benefit of low-dose cyclosporine to manage 
erosive OLP patients. Fourteen patients diagnosed with the erosive form of OLP were 
instructed to either rinse with a placebo or 5 ml (500 mg) cyclosporine rinse for 5 
minutes each day over the course of 28 days. Patients were then seen weekly to record 
lesion size and features as well as to assess healing, which was defined as a transition 
from ulceration to erythema to reticulation or to complete remission. A VAS was also 
done to assess pain. At 28 days, all experimental group patients experienced significant 
improvement in healing when compared to the placebo patients with no significant side 
effects noted.58 
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 Thongprasom et al compared cyclosporine solution in an adhesive base to 0.1% 
triamcinolone acetonide in a group of 13 Thai patients: Six were assigned to the 
cyclosporine group and the remaining seven were assigned to the triamcinolone group. 
Patients were instructed to use their gel TID for 8 weeks with follow-up at 2 and 8 weeks 
to assess pain using a 100 mm VAS and clinical response via the scale developed by the 
primary author. Further follow-ups were conducted every 3 months up to one year. After 
treatment, both groups experienced benefit, but there were no statistically significant 
differences in symptoms or clinical response at any time point between either treatment. 
Their results indicated that topical cyclosporine was not better than triamcinolone in 
treating OLP.59 
Tacrolimus 
 Tacrolimus, like cyclosporine, is also a calcineurin inhibitor and has been 
proposed as a potential treatment for OLP. Hodgson et al studied whether or not 
tacrolimus would be a successful treatment in OLP lesions resistant to traditional topical 
steroid therapy. Fifty patients with erosive or atrophic OLP were given 0.1% tacrolimus 
to use topically twice a day for an average treatment time of 19.8 months. Most of the 
patients (80%) experienced partial resolution, 14% achieved complete remission, and 
only 6% had no beneficial effect. During usage, 16% of patients reported burning 
sensations that were transient and even fewer (8%) reported taste disturbance.60 
Swift et al examined the efficacy of pimecrolimus, which has a similar structure 
and mechanism of action to tacrolimus. Pimecrolimus is derived from Streptomyces 
hygroscopicus var. ascomyceticus. In their study, 20 patients with erosive OLP split into 
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2 equal groups were treated for 4 weeks with either a placebo or 1% pimecrolimus 
ointment. Photographs were taken and analyzed and discomfort scores using a VAS 
were recorded bi-weekly. At the end of the study, the test group had significant 
reduction in overall lesion size; the control group experienced increased lesion size as 
well as minimal change or increase in pain scores. Ulcerative lesions trended towards a 
decrease in the test group and increase in the control group, but neither was significantly 
different at the mid-point nor at the end of the study from baseline measures. For 
erythematous lesions, the test group experienced a significant decrease in size at the 
mid-point compared to baseline whereas the control group did not. For the reticular 
lesions, the authors noted a significant increase in area of the reticular lesions at mid-
point and final evaluation when compared to baseline for the control group. No 
statistical significance was found for the test group in regards to reticular lesions. When 
the weighted sums of all lesions were calculated, there was no statistically significant 
reduction in the size of the lesions between the test and control groups. For pain, the test 
group experienced a significant decrease in symptoms compared to the control. They 
concluded that based on the results, 1% pimecrolimus is a safe and effective treatment 
alternative for erosive symptomatic OLP.61 
 Laeijendecker et al sought to compare 0.1% tacrolimus with 0.1% triamcinolone 
acetonide in a group of 40 patients treated for 4 weeks. Group I (n = 20) received 
triamcinolone and Group II (n = 20) received tacrolimus. Both groups were instructed to 
use the gel four times a day for 4 weeks; examination of clinical efficacy was scored as 
healed if no visual signs of OLP lesions remained, improved if the extent and severity 
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was reduced by more than 30%, and unchanged if the extent and severity was reduced 
by less than 30%. At 6 weeks, a higher percentage (90%) of patients had either healed or 
improved scores in the tacrolimus group compared to the triamcinolone group (45%). 
However, 40% of the tacrolimus users experienced burning sensations associated with 
the site of application.62 
Retinoids 
 Retinoids are a class of compounds chemically similar to Vitamin A and have 
regulatory effects on cell proliferation, growth of bone tissue, immune functions, and 
activation of tumor suppressor genes. Buajeeb et al compared patients using 0.05% 
retinoic acid gel to patients using 0.1% fluocinonide in an oral base. Eighteen patients 
received 0.1% fluocinonide acetonide and another 15 patients received 0.05% retinoic 
acid and were instructed to use either gel for 4 weeks. Results were assessed using a 10 
cm VAS as well as clinical response based on the scoring system by Thongprasom et al. 
At the end of the follow-up period, 83% of patients in the fluocinonide group 
experienced improvement in clinical signs compared to only 13% in the retinoic acid 
group. There was a clear general downward trend in the VAS for the fluocinonide users 
and the retinoic acid users as well but the latter was much more varied. This study 
suggests that although retinoic acid may be beneficial, it does not appear to be superior 
to topical steroids in treatment of OLP.63 
Piatelli et al studied the efficacy of 13-cis-retinoic acid (isotretinoin) for the 
treatment of biopsy-confirmed OLP. Ten patients were given 0.1% isotretinoin gel and 
another 10 were given a placebo gel formulation to apply four times a day for 4 months. 
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At the end of the initial 4 months, the placebo patients were given isotretinoin for a 
further 4 months. They assessed the prevalence of complete and partial response as 
disappearance of the lesion and 50% or more reduction in lesion sizes respectively. At 
the end of the initial 4 months, 4 of the 10 test patients had complete remission and 
another 4 had partial response compared to none in the placebo group. After the placebo 
patients used isotretinoin for a further 4 months, 6 of these patients had complete 
remission and the other 4 had partial responses. At the 3-year follow up, the lesions had 
recurred in 6 of the original 20 patients. The authors suggested that isotretinoin may be 
helpful in combating OLP.64  
Others 
 Wu et al looked at the plausibility of thalidomide as a topical medication for the 
treatment of OLP since thalidomide decreases TNF-α secretion and promotes T-cell 
suppression. Sixty-nine patients with biopsy-confirmed erosive oral lichen planus were 
divided into a group using 1% thalidomide rinse (Group A, n = 37) and another using 
0.043% dexamethasone (Group B, n = 32). Both patients and researchers were blinded to 
the treatment medication. Patients were instructed to rinse three times a day for 1 week. 
Patients who did not achieve complete remission, defined in this study as VAS of 0 and 
the resolution of erosive lesions, were instructed to use the gel another 3 weeks. After 
accounting for dropouts, the 33 patients receiving topical thalidomide experienced a 
significant average reduction in lesion size, erosive area, and VAS at 1 week as did the 
dexamethasone group. Eighteen of the 33 thalidomide users experienced complete 
healing of the erosive lesions compared to 17 of the 30 dexamethasone patients. It 
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appeared that thalidomide was equally as effective as dexamethasone in reducing VAS 
and clinical signs of erosive OLP. As for adverse effects, 4 patients complained of 
transient burning and tingling at the sites of administration of the thalidomide. 
Otherwise, no undue side effects were noted and no adverse outcomes associated with 
thalidomide were observed in either group at 1 year.65 
 Salazar-Sanchez et al evaluated Aloe vera as a topical drug. 70% Aloe vera was 
given to 32 patients and a placebo was given to 32 patients in the control group. All 
patients were instructed to use the gel three times a day for 12 weeks. Pain was rated 
using the VAS, and clinical efficacy of treatment was classified by a scale developed by 
Thongprasom et al. The results indicated that Aloe vera was not statistically different in 
alleviating pain based on the VAS. However, the Aloe vera group achieved a statistically 
higher number of patients with complete remission as compared the placebo group at 6 
week although this difference disappeared at 12 weeks. The authors suggested that 70% 
Aloe vera may quicken the healing time of patients with OLP in the short term.66 
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Oxidative Stress 
Reactive Oxygen Species 
Free radicals are defined as any chemical species which are able to exist with one 
or more unpaired electrons. They are highly reactive species and are capable of 
oxidizing, or causing loss of electrons, other substances. The first radical described in 
organic chemistry was the triphenylmethyl radical by Gomberg in 1900 at the University 
of Michigan. In 1956, Harman proposed the idea of free radicals playing a role in aging 
which ushered in an era of interest in free radical effects on biologic systems.67 This idea 
was inspired by Gerschman’s observation that both radiation and hyperbaric oxygen 
toxicity could be attributed to oxygen free radicals.68 Later in 1969, McCord and 
Fridovich from Duke University discovered superoxide dismutase (SOD), which is an 
important antioxidant enzyme responsible for partitioning superoxide radicals. Their 
discovery supported the concept of free radicals in living systems.69 In 1977, even more 
interest was given to free radicals after Mittal and Murad discovered that hydroxyl 
radicals were capable of initiating the cGMP messaging system.70 
Reactive oxygen species (ROS) are generally able to form other potentially 
damaging radicals with actions similar to true free radicals. Central to the action of ROS 
is the concept of redox potentials, which is the measure (in volts) of the affinity of a 
substrate for electrons measured in relation to hydrogen. Substances that have the ability 
to oxidize hydrogen are more electronegative than hydrogen and have positive redox 
potentials. Conversely, substances capable of reducing hydrogen are less electronegative 
than hydrogen and have a negative redox potential. Free radicals in the body can be 
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found from exogenous sources such as, but not limited to heat, trauma, ultrasound, UV 
radiation, ozone, smoking, exhaust fumes, radiation, infection, excessive exercise, and 
some drugs.72 Endogenous sources include superoxide leakage from the mitochondrial 
electron transport chain73 and from phagocytes during host immune responses as well as 
other connective tissue cells (osteoclasts and fibroblasts). Mitochondrial DNA is most 
susceptible to damage from free radicals due to the proximity to the electron transport 
chain as well as a lack of histones protecting genetic material despite the activity of 
superoxide dismutase 2.72 Phagocytic cell production of superoxide comes from the 
“respiratory burst” seen within PMNs in response to mitogens. This “burst” occurs when 
glucose-6-phosphate is shunted from glycolysis and forms superoxide radicals from an 
interaction with molecular oxygen and NADPH.74 
ROS can interact with and damage all types of physiologic systems. Dean et al 
described the effects of free radicals on proteins. These effects include: protein folding 
or unfolding, protein fragmentation and polymerization reactions, protease degradation 
of the modified protein, formation of protein radicals, formation of protein-bound ROS, 
or formation of stable end products.75 
ROS can also interact with lipids. Lipid peroxidation is one of the major 
reactions involving free radicals. Halliwell and Gutteridge described the main stages in 
this process. In the initiation step, a hydroxyl radical removes a hydrogen atom from a 
polyunsaturated fatty acid, such as arachidonic acid, and forms a carbon-centered 
radical. This carbon-centered radical can combine with another polyunsaturated fatty 
acid side-chain radical to link and disrupt the membrane structure via a covalent bond. 
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This interruption in the membrane structure causes Ca2+ influx and subsequent increase 
in Ca2+-dependent proteases disrupts cellular function. Most commonly, however, the 
carbon-centered radicals initiate a chain reaction by combing with oxygen to form a lipid 
peroxyl radical. These radicals can then bind to another polyunsaturated fatty acid to 
form another carbon-centered radical and a lipid hydroperoxidase. The latter two 
compounds propagate the same series of reactions creating an overwhelming 
accumulation of lipid hydroperoxidases which ultimately collapses the cell membrane. 
The final products of the lipid peroxidation are mainly malondialdehyde (MDA) and 4-
hydroxy-2-nonenal (HNE). MDA is mutagenic in mammalian cells as well as 
carcinogenic in murine models.76 
DNA damage from ROS is usually a result of strand breakage, base pair 
mutations, deletions, insertions, nicking, DNA cross-links, and sequence amplification 
by free radicals.77 Free radicals and ROS can also activate gene transcription resulting in 
induction of cellular apoptosis78 , activation of NF-κB and activator protein-1 (AP-1),79 
and activation of heat-shock proteins.80 NF-κB is important since its transcription is 
linked with production of proinflammatory cytokines such as IL-1, -6, and -8, MHC 
class I antigens, and TNF-α. 
The human body has an innate ability to keep the balance between ROS activity 
and antioxidant defense to curtail detrimental cellular damage. However, sometimes the 
delicate and dynamic equilibrium shifts in favor of too much ROS. This results in 
oxidative stress, which Sies defined as “a disturbance in the pro-oxidant–antioxidant 
balance in favor of the former, leading to potential damage.”81  
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Taken together, the resulting damage to cellular and genetic tissues from ROS 
and the increase in oxidative stress contributes to various pathologic conditions which 
can be divided into two major groups. The first group of diseases is caused by a pro-
oxidation shift in the redox state and is associated with cancer and diabetes mellitus. The 
second group of diseases are caused by an increase in either NAD(P)H oxidase (leading 
to atherosclerosis and chronic inflammation) or xanthine oxidase-induced formation of 
ROS (leading to ischemia and reperfusion injuries)82 Aging is attributed mainly to the 
damage from free radicals to lipids, DNA, and proteins.67 
Particular interest has been given to the role of ROS in carcinogenesis and 
several mechanisms and pathways have been studied. Aside from the DNA damage 
described above and exogenous sources of free radicals such as iron, cadmium, 
hexavalent chromium, arsenic, and tobacco smoke, there are intracellular factors which 
may induce cancer cell formation. One possible mechanism is mutation in various 
mitochondrial genes encoding complexes I, III, IV, and V. Another is via the production 
of MDA after lipid peroxidation since MDA can attach to guanosine, adenine, and 
cytosine bases of DNA and HNE can increase transduction of signals involved in cell 
phenotype.83 Another pathway of carcinogenesis is through the interference of signal 
transduction pathways. For example, ROS can promote expression of c-fos and c-Jun 
genes, which in turn promote cell proliferation. Activation of NF-κB indirectly by ROS 
via TNF-α and IL-6 induction promotes cell growth, proliferation, and inflammation.77  
Hollstein et al found that genes encoding for tumor suppressor p53, which prevents cells 
with damaged-DNA from dividing, can be directly damaged by ROS.84 
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With relation to the development of cardiovascular disease, ROS can induce 
damage in cardiac and vascular myocytes through the disruption in cell membrane 
structure by lipid peroxidation which allows for an overload of Ca2+. The influx and 
resultant hyperplasia of the intima contributes to atherosclerosis, vasoconstriction, 
hypertension, and cardiac hypertrophy in heart failure. Another association between 
ROS and cardiovascular disease is through the relation between ROS and Angiotensin II. 
It has been shown that Angiotensin II increased superoxide production by vascular 
smooth muscle cells.85 Kasporova et al showed that during reperfusion after ischemic 
cardiac events, there is a massive burst of ROS from a currently unknown source on the 
cellular level that causes massive amounts of damage to tissues and complicates organ 
transplantation, myocardial infarcts, and strokes.86 
Another large body of evidence of the role of ROS in systemic diseases involves 
type 2 diabetes mellitus (DM). Type 2 DM is a chronic disease in which the β-cells of 
the pancreas lose the ability to produce insulin. Evans et al observed that pancreatic 
cells, particularly β-cells, are sensitive to ROS as they have low levels of intrinsic 
antioxidants such as catalase, glutathione peroxidase, and SOD.87 ROS can also be 
produced in a diabetic state. In diabetes, the major source of ROS is from mitochondrial 
membrane complex II.88 Another source of ROS in diabetes is from NAD(P)H.89 
Anti-Oxidants 
To combat the damage from a variety of ROS in the body, a diverse and equally 
dynamic antioxidant defense system exists. Halliwell defined an antioxidant as “those 
substances which, present at low concentrations compared to those of an oxidizable 
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substrate, will significantly delay or inhibit oxidation of that substrate.”90 Chapple and 
Matthews presented 5 possible ways to categorize differences among antioxidants: 1) 
mode of action, 2) location, 3) solubility, 4) structures they protect, and 5) by their 
origin.72 Classifying by mode of action, there are preventative and scavenging 
antioxidants. Preventative antioxidants remove superoxide and hydrogen peroxide or 
prevent hydroxyl radical formation by sequestering divalent metal ions. These include 
superoxide dismutase enzymes 1 and 2, catalase, glutathione peroxidase, and DNA 
repair enzymes.76 Scavenging antioxidants, which are also known as chain-breaking 
scavengers, include Vitamin C, carotenoids, uric acid, flavonoids, ubiquinone, albumin, 
and bilirubin.72 
Of particular interest in this study are the class of scavenging antioxidants known 
as flavonoids which are absorbed from dietary wines, fruits, vegetables, and tea. 
Flavonoids function through many different mechanisms such as radical scavenging, 
terminating lipid peroxidation, iron chelation, sparing vitamin E, and restoration of 
vitamin C. Among flavonoids, two are of particular interest: ferulic acid and phloretin. 
Ferulic Acid 
 Ferulic acid (FA) is a polyphenolic compound found in all plants and is formed 
from metabolism of phenylalanine and tyrosine. It was discovered by Hlasiwetz and 
Barth in 1866 in Innsbruck, Austria from the resin of the Ferula foetida plant. Major 
fruit and vegetable sources include oranges, tomatoes, carrots, and sweet corn. The 
source of its antioxidant capability comes from its chemical structure. The phenolic 
nucleus and unsaturated C-C double bond side chain allows FA to readily accept a 
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hydrogen atom to form a phenoxy radical. This phenoxy radical is stabilized due to the 
chemical structure and is incapable of propagating another free radical chain reaction. 
Compared to other antioxidants such as Vitamin C, FA tends to remain in plasmatic 
circulation for a longer time period and is more bioavailable. Once FA is absorbed by 
enterocytes, only about 51% is excreted whole the other 49% is available to diffuse into 
the peripheral tissues.91 In addition to its antioxidant actions, many other beneficial 
effects of FA have been studied such as antidiabetic, antiatherogenic, hepatoprotective, 
and UV-protective benefits.92 Another key benefit relates to suppression of chronic 
inflammation. Hosada et al reported that FA blocks COX-2 induction93 and Sakai et al 
reported that it can also block murine chemokine (C-X-C motif) ligand 2, which is a 
chemotactic for PMNs.94  
Some studies have looked into the anti-carcinogenic properties of FA. 
Balakrishnan et al induced oral squamous cell carcinoma (SCC) in male hamsters by 
painting the buccal mucosa with 7,12-dimethylbenz[a]anthracene (DMBA) in a paraffin 
vehicle. The hamsters were divided into 4 groups of ten: Group I was painted with 
paraffin only and served as a sham control; Group II and III were both induced by 
DMBA but Group III was given FA orally on alternating days with DMBA painting; 
Group IV was not induced and was given ferulic acid only. After 14 weeks, the 
incidence of tumor formation, tumor burden, and tumor volume was assessed. They 
found that 100% of the hamsters had SCC in Group II, but none of the hamsters in the 
other three groups developed any tumors. Tissue levels of TBARS (thiobarbituric acid-
reactive substances), which is a marker of lipid peroxidation, and several antioxidants 
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(glutathione, superoxide dismutase, catalase, Vitamin A and C) were measured using 
histological assays. They found that TBARS was highly elevated and antioxidant levels 
were significantly decreased in Group II and that antioxidant levels in Group III, 
although significantly less than Group I or IV, was markedly higher than Group II.95 
 Kampa et al studied the effects of FA and several other polyphenol antioxidants 
on the proliferation and apoptosis of human breast cancer cells. Treatment of plated 
T47D breast cancer cells with the different antioxidants significantly reduced cell 
proliferation in a dose-dependent manner and apoptosis was induced.96 
 Lee et al studied the anticarcinogenic effects of FA and caffeic acid on human 
liver cancer cells. They assessed intracellular levels of ROS and cell viability of HepG2 
hepatoblastoma cells via MTT staining after treatment with either caffeic acid or FA. 
They observed that both CA and FA were cytotoxic and reduced cell viability to about 
50% from baseline. Flow cytometry indicated that this decrease in cell viability was a 
result of increased apoptosis induced by CA and FA in a dose-dependent manner.97 
Phloretin 
 Phloretin is a major constituent of apple polyphenols. Its antioxidant capacity, 
like FA, also arises from its chemical structure and is attributed to the carbonyl side 
group since hydrogen atoms can be delocalized over the three oxygen atoms.98  
 Devi and Das studied the effect of eleven different plant polyphenols on the 
growth and cytokine profile of normal human lymphocytes as well as two lines of 
malignant human leukemic lines (IM-9 and Molt-4). Their results showed that several 
polyphenols inhibited lymphocyte growth. The most potent, in order, were tannic acid, 
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phloretin, taxifolin, and fustin. These four were subsequently tested on leukemic cell 
lines to assess their ability to inhibit growth and were able to significantly inhibit cell 
proliferation of the leukemic cells as well as the proliferation of IL-2. Based on the 
results, the authors suggested that further research on plant polyphenols, particularly 
tannic acid, phloretin, taxifolin, and fustin.99 
 Jung et al studied 21 apple polyphenols and analyzed their ability to reduce 
proinflammatory gene expression by several immunorelevant cell lines induced with 
specific stimuli. They also looked at the effect on NF-κB-dependent signal transduction. 
Quantitative real-time PCR and DNA microarray analysis revealed that apple 
polyphenols significantly inhibited the expression of NF-κB regulated proinflammatory 
genes (TNF-α, IL-1β, CXCL9, CXCL10), inflammatory enzymes (COX-2, CYP3A4), 
and transcription factors (STAT1, IRF1). The effects did not carry over to healthy, 
homeostatic genes. Phloretin compounds, in particular, inhibited the NF-kB signal 
transduction cascade. The authors suggested that phloretins may play a role in inhibiting 
proinflammatory cytokine released via blocking of gene expression.100  
Combinations 
After the many beneficial effects of these individual antioxidants had been 
extensively studied, San Miguel et al studied different antioxidants (AO) and evaluated 
their ability to promote cell migration in the presence of nicotine. They looked 
specifically at the ability of resveratrol, phloretin, ferulic acid, and curcumin in 
activating RacGTPases. Rac is an enzyme which participates in cell signaling during cell 
migration. Rac, which is a member of the Rho-family small GTPase, cycles between an 
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active state (GTP-bound) and an inactive state (GDP-bound). The investigators took 
human gingival tissues from healthy, non-smokers as well as HDPL fibroblasts from 
freshly extracted human teeth. The cells were plated on a special 35-mm culture dish that 
was divided into quarters which allowed for high-quality phase-contrast observation. 
The cultured cells received varying doses of nicotine (6, 8, or 10 mM) for 2 hours and 
were then treated with single, double, or triple AOs. Cell migration as observed every 15 
minutes for 10 hours under a live-cell imaging system. To assess RacGTP activity, a 
scratch-wound assay was performed using a pipette tip. Antibodies for RacGTP and IgG 
were added and the level of RacGTP was assessed using confocal microscopy. The 
results showed that nicotine reduced cell viability by 40% to 50%. For all single AO 
combinations, FA was the most effective in increasing migration rates compared to the 
controls and nicotine-treated HGF cells and resveratrol was the most effective in 
increasing cell migration compared to the controls and nicotine-treated HPDL cells. For 
double combinations, RF and PF increased migrations rates significantly better than any 
single AO dose and the controls. Finally, all triple combinations improved cell migration 
significantly more than any double combination. The authors concluded that although 
triple combinations of AO were the best in improving cell migrations of HGF and HPDL 
cells after treatment with nicotine, any singly-administered AOs significantly improved 
cell migration compared to the controls. As for the RacGTP assay, any combination of 
AO significantly enhanced the level of RacGTP expression when compared to the 
controls in HGF cells treated with nicotine. However, the HPDL cells treated with 
nicotine did not improve in terms of RacGTP expression with any combination of AO. 
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Indeed, there was a significant difference in RacGTP expression after AO treatment 
between the HGF and HPDL cells.101 
 San Miguel et al followed up their previous research by looking at the effects of 
specific AO combinations on the level of cell viability, DNA synthesis, and ROS activity 
after treatment of HGF and HPDL cells treated with different stressors (H2O2, EtOH, or 
nicotine). Both types of cells were cultured and exposed to varying doses of irritants (6 
mM and 8 mM of nicotine, 5% and 10% EtOH, and 0.0005% and 0.00075% of H2O2). 
Afterwards, the cells were treated with either a combination of RFT (resveratrol, ferulic 
acid, and tetrahydrocurcuminoids CG in a 1:1:1 ratio), PFR (phloretin, ferulic acid, and 
resveratrol in a 1:1:1 ratio), or PFT (phloretin, ferulic acid, and tetrahydrocurcuminoids 
CG). Cell viability was assessed using MTS colorimetric assay, DNA synthesis was 
assessed using the BrdU assay, and ROS was assessed using the 
dichlorodihydrofluorescein diacetate (H2DCFDA) reagent. Treatment with any 
combination of AOs had a marked positive effect on HGF cell viability after treatment 
with EtOH; HGF cell viability increased to over 100% of the control after treatment. 
After treatment with any of the AO combinations, the HGF cells exposed to nicotine 
exhibited 2.5-3 fold increase in cell viability. HGF cells treated with any of the AO 
combinations after exposure to 0.00075% H2O2 showed a significant increase in cell 
viability, but only the PFR increased cell viability of cells exposed to 0.0005% H2O2. 
After treatment of HGF cells with 0.0005% H2O2, RFT and PFR significantly increased 
DNA synthesis from baseline. For the cells treated with 0.00075% H2O2, only the RFT 
significantly increased DNA synthesis from baseline. Only HGF cells treated with PFR 
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were able to increase DNA synthesis after exposure to either 5% or 10% EtOH, and only 
HGF cells treated with PFT were able to increase DNA synthesis after exposure to 
nicotine. HPDL cells treated with PFR were able to recover in terms of DNA synthesis 
after they had been exposed to nicotine. Similar results could be seen in decreasing the 
levels of ROS after each one of the stressors had significantly increased the levels of 
ROS.102 
 In another study, San Miguel et al examined the potential of certain antioxidant 
combinations to protect fibroblasts against metal-induced toxicity. Metal ions released 
from metals such as Zn, Cu and Ni in restorative materials can induce fibroblast and 
osteoblast apoptosis. They took human gingival fibroblast cultures and human 
periodontal ligament cell cultures from donors and exposed them to copper (Cu), zinc 
(Zn), or nickel (Ni) in various doses. Afterwards, the cells were treated to one of three 
combinations of AOs: 1) “RFT,” a 1:1:1 by weight ratio composition of resveratrol, 
ferulic acid, and tetrahydrocurcuminoids, 2) “PFR,” a 1:1:1 by weight ratio composition 
of phloretin, ferulic acid, and resveratrol, or 3) “PFT,” a 1:1:1 by weight ratio 
composition of phloretin, ferulic acid, and tetrahydrocurcuminoids. Cell viability was 
tested via MTS calorimetric assay, the ability of the remaining live cells to synthesize 
DNA was tested with the BrdU assay, and reactive oxygen species was assessed using 
dichlorodihydrofluorescein diacetate (H2DCFDA) reagent. They found that all 
combinations of AO significantly increased the viability of HGF and HPDL cells after 
treatment of 4 x 10-4 M Cu, and increased the viability of HPDL cells after treatment 
with 5 x 10-4 M Cu. All combinations of AO significantly increased viability of HGF 
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cells after treatment with 2 x 10-3 M Ni. All combinations of AO significantly increased 
the viability of HGF cells after treatment with 3 x 10-4 M Zn and also increased after 
treatment with 2 x 10-4 M Zn, but this was not significant. However, none of the HPDL 
cells responded to any AO combinations after treatment with any dose Zn or Ni. Only 
the combination PFT increased HGF DNA synthesis significantly after Cu exposure had 
reduced DNA synthesis, but all AO combinations significantly increased HPDL DNA 
synthesis. All AO combinations significantly increased HGF and HPDL cell DNA 
synthesis after exposure to Ni. PFR and PFT combinations were able to rescue HGF cell 
DNA synthesis after treatment with Zn, and all combinations were able to rescue HPDL 
cell DNA synthesis after exposure to Zn. Only the combination of PFR decreased the 
ROS after treatment with Cu, Ni, and Zn. The authors concluded that various 
combinations of AO helped HGF and HPDL cells recover in terms of viability and DNA 
synthesis and reduced ROS after exposure to various concentrations of metal ions. The 
combination PFR seemed to be the most beneficial.103 
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Oxidative Stress and Oral Lichen Planus 
Although many etiologic mechanisms have been explored as presented above, 
only recently has attention been given to the potential role of oxidative stress in the 
pathogenic process of oral lichen planus.   One of the first key investigations in the 
search for a potential relationship between oxidative stress and OLP was a cross-
sectional study by Sezer et al. They studied serum levels of nitric oxide (NO), SOD, 
MDA, and catalase (CAT) in 40 patients with untreated lichen planus with onset of 
symptoms within 6 weeks and compared them to 40 healthy volunteers matched for sex 
and age. All patients presented with cutaneous lesions and 9 patients had additional oral 
lesions. Their results showed that NO, MDA, and SOD were present in significantly 
higher levels in serum of test patients compared to controls and serum CAT was 
significantly lower in test patients compared to controls.104 
 Battino et al evaluated levels of serum uric acid, albumin, glucose, total 
cholesterol, HDL-cholesterol, triglycerides, aspartate transaminase (AST), alananine 
transaminase (ALT), γ-glutamyltransferase (GTT), and total antioxidant capacity (TAC) 
as well as salivary levels of uric acid, albumin, and total antioxidant activity from 20 oral 
lichen planus patients compared to 20 healthy controls. Their results showed that 
salivary uric acid levels and TAC were significantly lower in the OLP group compared 
to the controls while serum GTT was significantly increased in the OLP group.105 
 In a similar study to Sezer et al, Aly and Shahin studied 45 Egyptian patients 
with different forms of lichen planus and compared levels of serum superoxide 
dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), and catalase (CAT) to 
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those of 45 healthy volunteers matched for sex and age. Blood was collected after 12 
hours of fasting and analyzed. Cutaneous lesions were present in all test patients and oral 
lesions were present in 26 patients (57.7%) with the reticular form being the exclusive 
type of oral lesion. Their results showed that serum levels of NO, MDA, and SOD were 
all significantly higher compared to control patients. They also found that NO, MDA, 
and SOD levels increased significantly and CAT levels decreased significantly in 
patients with oral manifestations and skin lesions. They conclude that their evidence 
supports investigating the use of antioxidants in the treatment of oral lichen planus.106 
 Upadhyay et al examined levels of MDA, thiol levels, and TAC in the serum of 
22 untreated OLP patients, 10 untreated patients with oral lichenoid reactions and 15 
healthy controls matched for age and gender. They found that the level of MDA was 
0.7595 ± 0.536 mM/L in OLP patients, 0.4890 ± 0.216 mM/L in the OLR group, and 
0.2187 ± 0.054 mM/L in the control group. The difference between the OLP patients and 
the OLR patients to the control group was significant. For thiol levels, OLP patients had 
378.26 ± 1.50 mM/L compared to 472.13 ± 54.27 mM/L in the controls. This difference 
was also significant. As for TAC, both the OLP and OLR samples had much lower 
levels of TAC (1.054 ± 0.3013 mM/L and 1.019 ± 0.2435 mM/L respectively) compared 
to the controls (2.037 ± 0.1382 mM/L).107 
 In another study, Ergun et al evaluated the total antioxidant activity (TAA) and 
levels of malondialdehyde in whole saliva and serum of 21 recently diagnosed, untreated 
OLP patients and 20 healthy control patients matched for periodontal status. Serum and 
saliva samples were taken after a midnight fast, centrifuged, and tested for TAA and 
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MDA levels. Univariate analyses included independent samples t-test, Mann-Whitney 
U-test, and Spearman’s rho correlation coefficient. The results showed that patients with 
OLP had significantly higher salivary MDA levels (p = 0.03) and lower serum TAA 
levels (p = 0.01) compared to the control patients. The results also indicated a significant 
inverse relationship between MDA and TAA levels in saliva (r = -0.598, p = 0.005). The 
authors suggest that levels of antioxidants and oxidative stress markers can be measured 
accurately in saliva and that patients with OLP have higher salivary levels of lipid 
peroxidation.108 
 Furthermore, Scrobotǎ et al studied the levels of MDA and GSH (glutathione, a 
marker of antioxidant defense) in tissue obtained from biopsies of 9 patients with OLP 
and 4 healthy volunteers using a fluorometric method. They found the median level of 
MDA in OLP tissue samples was 2.67 (0.26–3.40) compared to 0.44 (0.19–0.70) for the 
control tissues and the levels of GSH in OLP tissue samples was 2.3 (1.25–5.70) 
compared to 9.56 (6.5–12.5) for the control tissues. Both differences were statistically 
significant.109 
 Aziz et al examined the levels of total antioxidant status (TAS) in the saliva and 
serum of 48 erosive OLP patients and 44 healthy controls matched for age and gender. 
They found that the level of TAS was 0.98 ± 0.12 mM in erosive OLP patients and 1.32 
± 0.18 mM in the control group.110 
 Most recently, Agha-Hosseini et al examined salivary levels of 8-OHdG, MDA, 
and TAC in patients with squamous cell carcinoma (SCC) and oral lichen planus (OLP). 
Twenty-six SCC patients and 32 OLP patients were recruited after confirmation by 
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biopsy. Of the OLP patients, 20 had the erosive form and 12 had reticular lesions. Thirty 
healthy controls with no signs of inflammation were used as controls. Unstimulated 
whole saliva was collected after at least 2 hours of fasting and analyzed for levels of 8-
hydroxy-deoxyguanosine (8-OHdG), MDA, and TAC. They also calculated the balance 
of oxidant and antioxidant status by dividing the TAC by the level of MDA. Their 
results showed that SCC patients had a significantly higher salivary levels of MDA and 
8-OHdG and lower levels of TAC compared to the control group. OLP patients had 
significantly higher levels of salivary 8-OHdG compared to the controls, but levels of 
MDA and TAC were not statistically different from the controls. They also found that 
the TAC/MDA ratio was significantly lower in both SCC and OLP patients compared to 
the controls, but SCC was also significantly lower compared to OLP patients. The 
authors suggest that an imbalance between oxidative stress and antioxidant capacity 
plays an important role in OLP and that 8-OHdG may be a better marker for oxidative 
stress in OLP and SCC patients, and it may also be useful in indicating cancer risk.111 
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Antioxidants and Oral Lichen Planus 
 Although there is a moderate amount of literature to link oral lichen planus to 
oxidative stress, most of the literature has been relational and not interventional. One of 
the early interventional, prospective studies that looked at the use of antioxidants was 
performed by Chainani-Wu et al. Their group studied the efficacy of curcuminoids to 
treat OLP in a randomized, controlled, double-blind trial. Curcuminoids are similar to 
curcumin in chemical structure and have antioxidative benefits. The investigators 
enrolled 17 patients in the placebo group and 16 patients in the curcuminoid group. 
Patients were given prednisone for 1 week prior to using either the placebo or test gel. 
Those in the latter group received a formulation of “Curcumin C3 Complex” which 
consisted of curcumin in a range of 70 to 80%, demethoxycurcumin between 15% and 
25%, and bisdemethoxycurcumin between 2.5% and 6.5%. Despite a power analysis that 
suggested the need for 50 subjects per group, interim analysis after 33 patients were 
recruited and undergoing treatment revealed that there was no difference in reduction of 
symptoms or signs between the two groups. Futility analysis was performed and 
revealed that the probability of finding a significant result if the study was continued to 
the prescribed number of subjects was only 0.014; therefore the study was ended for 
futility. However, the authors still recommended future research.112 
 More recently, the only other prospective clinical trial for use of an antioxidant 
was by Saawarn et al. Their group evaluated the efficacy of lycopene in the treatment of 
oral lichen planus. Lycopene is a fat-soluble carotenoid which provides for the red color 
of tomatoes and some other fruits and is the most efficient singlet oxygen quenching 
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carotenoid. In their prospective, randomized, placebo-controlled, double-blind study, 
they treated 15 patients with 8 mg total daily of lycopene softgel capsules (Group A) and 
another 15 patients with a placebo (Group B) for 8 weeks. A VAS was used to record 
burning sensations at baseline, at 2 week intervals during treatment, as well as 30 and 60 
days after the completion of therapy. The treatment response was recorded using the Tel-
Aviv-San Francisco scale. The results showed that individuals taking the lycopene 
capsules experienced a significantly reduced VAS at 8 weeks (7.6 ± 9.2) compared to 
baseline (47.0 ± 22.9) with no difference in the VAS between the experimental and 
control groups after completion of the treatment. In the placebo group, there was a 
reduced VAS from baseline (49.0 ± 22.9) to 8 weeks (16.3 ± 18.3) with no difference in 
the VAS after completion of the treatment. Although there was a marked difference in 
the average reduction of the VAS between the control and test group, the difference was 
not statistically significant. The authors commented that this reduction in the placebo 
group correlates to the spontaneous remission often seen in OLP. However, when the 
examiners looked at the percentage of complete remission cases in either group, they 
found that 73.3% of patients in the lycopene group experienced remission whereas only 
26.7% of the placebo group experienced remission. Based on these findings, the authors 
surmised that lycopene, which carries antioxidant properties, is effective at reducing the 
signs and symptoms of OLP.113 
 As reported in the literature presented above, there appears to be a lack of clinical 
research relative to the use of antioxidants in the management of patients with oral 
lichen planus. Adequate research has linked a state of oxidative stress to the intraoral 
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manifestations of OLP, but stronger interventional studies employing antioxidants is 
critical to establish the strength of the relationship. Should antioxidants improve the 
clinical condition of patients afflicted with this chronic, cyclical disease, more research 
is indicated at elucidating the mechanism of action by which reactive oxygen species and 
free radicals promote signs and symptoms. Although topical steroids remain an effective 
and safe choice for treatment, they are not without potential problems such as oral 
candidiasis. Based on today’s healthcare trends, patients often seek all-natural 
alternatives and remedies. Antioxidants may fit the bill as most are derived from 
different fruits, vegetables, and other plants. 
 The purpose of this study is to test the efficacy of a combination topical 
antioxidant formulation containing ferulic acid and phloretin in treating patients with 
signs and symptoms of oral lichen planus. The primary outcomes include VAS for 
symptoms and assessment of clinical improvement based on a scoring system developed 
by Piboonniyom et al.114 Secondary measures include salivary MDA and 8OH-dG levels 
taken before and after treatment since no prospective interventional studies have studied 
the levels of oxidative stress after treatment. This study will be undertaken with the 
hopes of contributing to growing literature linking oral lichen planus to oxidative stress 
as well as offering clinicians and patients an alternative therapy capable of treating and 
controlling this disease. 
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METHODS AND MATERIALS 
Protocol Approval 
The research study was submitted to and approved by the Institutional Review 
Committee at Baylor College of Dentistry, Texas A&M University (Dallas, Texas, 
United States). 
Subject Population 
A total of 40 patients (8 males, 32 females with an age range of 32-86) with oral 
lichen planus were recruited from the Stomotology Clinic, Baylor College of Dentistry 
(Dallas, Texas, United States). 
Inclusion criteria included: (1) at least 18 years of age, (2) must speak and 
understand English, (3) documented diagnosis of OLP or lichenoid mucositis via biopsy, 
(4) active with signs and/or symptoms of OLP intraorally, (5) refractory to conventional 
therapy or incomplete response to conventional therapy after 6 or more weeks of 
therapy, (6) must be able provide verbal and written informed consent. 
“Unresponsiveness” is defined as no alleviation in signs and/or symptoms, and 
“incomplete” response is defined as an improvement in signs and symptoms but not to 
an acceptable level to the patient. 
Exclusion criteria were: (1) females who are pregnant, who are planning on 
becoming pregnant , or believe they may be pregnant or lactating females, (2) allergy to 
any ingredients in AO ProVantage Gel (phloretin, ferulic acid, menthol, peppermint oil, 
thyme, sage oil, clove flower oil, xylitol), (3) past or current use of any topical 
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antioxidant therapy applied intraorally, (4) history of oral malignancy or active oral 
infections, (5) having a diagnosis of hepatitis C or HIV, (6) bone marrow and/or kidney 
transplant recipients, (7) current smoker as defined by the WHO (reports smoking at 
least 100 cigarettes in their lifetime and, at the time of survey, smokes either every day 
or some days) or have used or are using smokeless tobacco, (8) uncontrolled diabetes 
mellitus with a hemoglobin A1c score greater than 7% ( 53 mmol/mol) (American 
Diabetes Association) using a chairside test (A1c Now +), (9) and having a known 
disease resulting in immunodeficiency. 
Experimental Design 
 Patients who agreed to participate in the study were placed into two groups: PLC 
(placebo, n = 20) or AO (test, n = 20). The placebo formulation was designed without 
the use of phloretin and ferulic acid, which are the two main anti-oxidant ingredients in 
the active product, and was of the same color, taste, viscosity, and smell. The company 
provided certification that the placebo formulations were indeed lacking in both 
ingredients. All tubes of the placebo and test gels were labeled by the company with 
either an A or B accompanied by a value from 1 to 20, and a decryption grid was kept by 
the company until all patients completed the study. 
 Patients were seen at baseline, 2 weeks, and 4 weeks. At the baseline evaluation, 
patients were asked to fast and refrain from using any form of topical medications from 
midnight until their appointment. The morning of their appointment, patients rinsed with 
sterile water for 30 seconds before saliva collection. Un-stimulated whole saliva was 
collected by having the patients tilt their heads down and drool saliva into a graded 
 48 
 
sampling tube until about 5 ml was collected. The collected saliva was immediately 
placed into a centrifuge (Hermle Z300K, Labnet International, Inc., Edison, NJ, USA) at 
1,250g for 10 minutes at 4°C and the supernatant was stored in 1 ml aliquots at -80°C. 
 Intraoral lesions were evaluated and scored based on the scoring system 
described by Piboonniyom et al114 with the aid of a transparency paper with rectangular 
and round shapes equaling 1 cm2 and 3 cm2. The mouth was divided into several areas 
and given a score for the type of lesion present. Reticular lesions were scored with either 
a “0” for the absence of lesions or a “1” for the presence of lesions. With the help of 
transparency paper (Fig. 1), erythematous and ulcerative lesions were scored as: “0” – no 
lesions present, “1” – lesions ≤1 cm2, “2” – lesions >1 cm but ≤ 3 cm2, and “3” - lesions 
>3 cm2. The final whole mouth composite score was the sum of the three types of lesions 
with the erythematous score multiplied by a factor of 1.5 and the ulcerative lesions 
factored by a factor of 2 (Fig. 2). Patients indicated what current therapy they were 
using, lesions were  photographed, and patients were asked to indicate their current 
symptoms using a 100 mm VAS scale with marks at every 5 mm (0 = no pain 
whatsoever, 100 = worst pain ever).  
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Figure 1. Example of measuring clinical lesions. Clear plastic outlines of circles or polygons (not 
shown) with areas of 1 cm2 and 3 cm2 were used to score erythematous and ulcerative lesions. 
 
 
Figure 2. Oral lichen planus scoring system 
 
 
 After examination, patients were given a tube of either the placebo or test gel. 
Randomization was achieved by writing all corresponding codes onto small squares of 
paper and placed into an unlabeled manila envelope. Patients selected one small square 
of paper and were given the tube with the corresponding code. The patients were 
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instructed to treat each area with symptoms or lesions with a pea-size amount of product 
3 times a day in a gentle dabbing motion and refrain from eating or drinking for 30 
minutes after each use. Patients were instructed to continue their current therapy for 
lichen planus during the duration of their participation, even if it included no treatment at 
all, to ensure equal baseline and final oral conditions. To ensure compliance, each tube 
was weighed in ounces before and after demonstration and at each subsequent recall in 
order to assess if the weight fell within a reasonable range (±20% of expected weight) 
which would indicate adequate usage. 
 Repeat photographs, VAS assessment, and OLP scoring were obtained again at 2 
weeks and 4 weeks, and saliva collection was repeated again at 4 weeks. 
Analysis of 8-OH-dG and MDA 
Saliva 8-OH-dG levels were assayed using a commercially available competitive 
enzyme immunoassay, DNA/RNA Oxidative Damage EIA Kit (Cayman Chemical, Ann 
Arbor, Michigan, USA), according to the manufacturer’s instructions. The enzyme 
immunoassay buffer consisting of 1 M phosphate solution containing 1% BSA, 4 M 
sodium chloride, 10 mM EDTA and 0.1% sodium azide was diluted with 90 ml of 
deionized water and the wash buffer consisting of 4 M phosphate solution was diluted to 
a volume of 2 liters of deionized water and 1 ml of polysorbate 20. Saliva samples were 
diluted with the enzyme immunoassay buffer to a 1 to 50 μl dilution and each sample 
was plated on a 96-well plate coated with goat polyclonal anti-mouse IgG. Fifty 
microliters of a tracer comprised of acetylcholinesterase linked to an 8-OH-dG and 50 μl 
of the mouse anti-human 8-OH-dG antibody were added to each sample. Each plate was 
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then covered with a plastic film and incubated for 18 hours at 4°C. The plate was then 
emptied and washed with the wash buffer and 200 μl of Ellman’s Reagent (5,5'-
dithiobis-(2-nitrobenzoic acid)) was added to each well. The plate was again covered 
with a plastic film and allowed to develop for 90-120 minutes. Afterwards, the film was 
removed and the plates were read at 450 nm with a spectrophotometer (FLUOStar 
Optima, BMG Labtech, Cary, NC, USA) and reported as pg/ml. 
Saliva MDA levels were assayed using a commercially available kit, NWLSS 
Malondialdehyde Assay (Northwest Life Science Specialties, Vancouver, Washington, 
USA), to measure adducts formed by the reaction of MDA with thiobarbituric acid 
(TBA). Thiobarbituric acid was reconstituted with 10.5 ml deionized water and 10 μl 
butylated hydroxytoluene in ethanol was added to microcentrifuge vials. The saliva 
samples were added to the vials and then subsequently combined with 250 μl 1M 
phosphoric acid and 250 μl TBA reagent. The vials were then vortexed, incubated at 
60°C for 60 minutes, and then centrifuged (Spectrafuge 24D, Labnet International, Inc., 
Edison, NJ, USA) at 10,000x g for 150 seconds. The reaction mixtures were transferred 
to semi-micro cuvettes, analyzed at 523 nm with a spectrophotometer (FLUOStar 
Optima, BMG Labtech, Cary, NC, USA), measured based on comparison with a 
calibrated standard, and reported as μM.  
Statistical Analysis 
For the VAS, a 20% reduction was considered to be clinically significant115. 
However, there were 12 total individual data sets with a baseline VAS of less than 20. 
We felt it was reasonable to keep these data sets since it might provide valuable clinical 
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results. One patient in the AO group dropped out after 1 week of usage due to frustration 
from a lack to symptomatic improvement. One patient in the PLC group dropped out 
after 3 weeks of usage due to similar frustrations. For intent-to-treat analysis, the data 
missing for the remaining time points was assumed to remain the same as the last 
recorded value for VAS, OLP, MDA, and 8-OH-dG. 
In addition to the incomplete data on the drop-outs, 2 additional patients had 
incomplete data for salivary MDA at 4 weeks due to laboratory error and a resultant loss 
of remaining sample from those patients. The MDA level from baseline was assumed to 
have remained the same in these cases. 
The final data was further stratified into groups of the patients with the highest 
value for each variable. The cut-off for ranking in these “high” groups was determined 
after data collection. If the sample size permitted, statistical analysis was performed. If 
not, descriptive statistics and observations for trends were used to describe any potential 
correlations between the different variables and clinical parameters such as lesion type 
and areas of involvement. 
All variables were treated as interval data and since the sample was not normally-
distributed, non-parametric tests were used. A Friedman test was used to test for 
universal differences among the repeated measures within each group. Post hoc 
Wilcoxon signed-rank tests were used to analyze within group differences from baseline 
to 2 weeks, 2 weeks to 4 weeks, and baseline to 4 weeks. Bonferroni corrections were 
used to adjust the α value for multiple comparisons (α = 0.05/3 = 0.0167). A Mann-
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Whitney U test was used to examine differences between the two groups at each time 
point. The significance value was set at α = 0.05. 
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RESULTS 
 
Of the 40 patients screened, 7 were disqualified. One patient had an Hba1c value 
> 7.0%, 3 had no clinical signs of OLP, and 3 others never made their baseline 
appointment. A total of 33 patients were included in the study. There were 17 patients in 
the PLC group (13 females and 4males, ages between 32 and 80, with an average age of 
61 ± 12.03 years) and 16 patients in the AO group (12 females and 4 males, ages 
between 44 and 86, with an average age of 65.69 ± 9.84 years). None were smokers and 
2 patients had type 2 diabetes mellitus, one with an Hba1c of 6%, and the other, 6.2% 
(Table 1). During the course of the study there were 3 drop-outs, 1 from the PLC group, 
and 2 from the AO group. Complete data was obtained up to the 2 week follow-up for 
the patients in the AO group, and while only baseline data was available for the PLC 
group drop-out. 
In terms of patient compliance, only one patient was disqualified from the study 
because he had used 32.28% more than the expected weight of the tube and ran out of 
the medication at 2 weeks. All other patients were within the arbitrary 20% range 
(average of -0.43% ± 6.87 for the PLC group, average of 5.51% ± 10.61% for the AO 
group, data not shown) of their expected tube weight at the 2 week visit. During the 4 
week visit, the average difference from the expected tube weight was 2.58% ± 16.69 for 
the PLC group and -0.10% ± 10.94 for the AO group; 5 patients were outside of the 20% 
range (average of 26.99% ± 4.58). However, the data was kept so the sample size would 
not be compromised during analysis. 
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Table 1. Patient characteristics 
Parameter PLC AO 
No. of patients 17 16 
Age 61.00 ± 12.03 years 65.69 ± 9.84 years 
No. of smokers 0 0 
No. of diabetic patients 1 1 
Hba1c 6.9% 6.7% 
Current therapy   
Clobetasol 10 9 
Fluocinonide 3 2 
None 3 4 
Other 1 1 
 
 
VAS 
 The mean values for the VAS at each time point are listed in Table 2. At 
baseline, the mean VAS for the PLC group was 31.41 ± 30.82 and 33.25 ± 28.82 for the 
AO group. At the 2 week follow-up, the PLC group had a mean VAS of 21.53 ± 23.75, 
and the AO group had a mean VAS of 14.25 ± 14.05. At 4 weeks, the PLC group had a 
mean VAS of 24.41 ± 24.44, and the AO group had a mean VAS of 16.75 ± 22.14. From 
baseline to 2 weeks, both groups had a statistically significant reduction in VAS (P 
<0.05). From 2 weeks to 4 weeks, neither group had further statistically significant 
reductions in VAS (P >0.05). Relative to the baseline, there was no difference at 4 
weeks for the PLC group, but the VAS for the AO group was statistically lower at 4 
weeks than at baseline (Table 2). However, there were no statistically significant 
differences between the PLC and AO groups at any of the time points (P >0.05). (Fig. 3)
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Table 2. Summary of VAS 
VAS PLC (n = 17) AO (n = 16) P values 
Baseline 31.41 ± 30.82 33.25 ± 28.82 0.678 
2 Weeks 21.53 ± 23.75 14.25 ± 14.05 0.612 
4 Weeks 24.41 ± 24.44 16.75 ± 22.14 0.336 
 
 
 
 
Figure 3. VAS progression.  * - P < 0.017 
 
 
Lesion Scoring 
 The mean values for the lesion scores at each visit are listed in Table 3. At 
baseline, the mean lesion score for the PLC group was 6.75 ± 3.48 and 7.79 ± 5.18 for 
the AO group. At the 2 week follow-up, the PLC group had a mean lesion score of 5.75 
± 2.86, and the AO group had a mean lesion score of 6.26 ± 4.10. At 4 weeks, the PLC 
group had a mean lesion score of 5.19 ± 2.52, and the AO group had a mean lesion score 
of 6.53 ± 4.63. The reduction in OLP lesion score from baseline to 2 weeks and from 
baseline to 2 weeks was statistically significant for the PLC group (P <0.05), and the 
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reduction of the OLP lesion score from baseline to 4 weeks was statistically significant 
for the AO group (P <0.05) (Table 3). However, after Bonferroni corrections, the 
reduction in OLP lesion score from baseline to 4 weeks for the PLC group failed to 
remain statistically significant. There were no statistically significant differences 
between the groups at any time point in terms of OLP lesion score (P >0.05) (Fig. 4). 
 
 
Table 3. Summary of OLP lesion scores 
OLP lesion score PLC (n = 17) AO (n = 16) P values 
Baseline 6.75 ± 3.48 7.79 ± 5.18 0.759 
2 Weeks 5.75 ± 2.86 6.26 ± 4.10 0.885 
4 Weeks 5.19 ± 2.52 6.53 ± 4.63 0.588 
 
 
Figure 4. OLP lesion score progression. * - P <0.017 
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Salivary 8-OH-dG 
The mean values for salivary 8-OH-dG at each visit are listed in Table 4. At 
baseline, the mean salivary 8-OH-dG (in pg/ml) for the PLC group was 179.01 ± 99.47 
and 216.88 ± 132.01 for the AO group. At 4 weeks, the PLC group had a mean salivary 
8-OH-dG of 193.58 ± 158.23 which was an 8.14% increase from baseline. At 4 weeks, 
the AO group had a reduced mean salivary 8-OH-dG level of 178 ± 116.56. This 
represented a 17.93% reduction in 8-OH-dG levels. Neither changes were statistically 
significant (P >0.05) (Table 4). When comparing both groups at baseline and 4 weeks, 
there were no statistically significant differences between the PLC and AO group at any 
time point (P >0.05) (Fig. 5). 
 
 
 
 
Table 4. Summary of salivary 8-OH-dG levels 
8-OH-dG (pg/ml) PLC (n = 17) AO (n = 16) P values 
Baseline 179.01 ± 99.47 216.88 ± 132.01 0.428 
4 Weeks 193.58 ± 158.23 178 ± 116.56 0.801 
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Figure 5. 8-OH-dG progression 
 
 
Salivary MDA 
The mean values for salivary MDA at each visit are listed in Table 5. At baseline, 
the mean salivary MDA (in µM) for the PLC group was 3.39 ± 1.07 and 3.24 ± 1.07 for 
the AO group. At 4 weeks, the PLC group had a mean salivary MDA level of 3.52 ± 
1.28 and 4.63 ± 1.82 for the AO group. There was no statistically significant change 
from baseline to 4 weeks for the PLC group (P >0.05), but the increase in the AO group 
was statistically significant (P <0.05) (Table 5). Although there was no statistically 
significant difference at baseline between the AO and PLC group (P >0.05), the AO 
group had a significantly higher level of MDA at 4 weeks compared to the PLC group (P 
<0.05) (Fig. 6). 
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Table 5. Summary of salivary MDA levels 
MDA (µM) PLC (n = 17) AO (n = 16) P values 
Baseline 3.39 ± 1.07 3.24 ± 1.07 0.471 
4 Weeks 3.52 ± 1.28 4.63 ± 1.82 0.019 
 
 
 
Figure 6. MDA progression; * - P < 0.05 
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Figure 8. Patient in the AO group at (A) baseline, (B) 2 weeks, and (C) 4 weeks. 
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Figure 7. Patient in the PLC group at (A) baseline, (B) 2 weeks, and (C) 4 weeks. 
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Descriptive Analysis 
Further investigation looked at the trends and possible relations between the 
variables. To simplify the data and focus on more severe symptoms and clinical 
presentations, we looked at the data which was the highest for all categories at baseline 
using arbitrary cutoffs. “High” scores for VAS were considered to a VAS ≥ 50, an OLP 
lesion score ≥ 9, 8-OH-dG levels ≥ 210 pg/ml, and MDA levels ≥ 3.900 μM. The “high” 
VAS group consisted of 8 patients with an average baseline VAS of 78.25 ± 13.25, the 
“high” OLP group consisted of 10 patients with an average baseline OLP score of 12.7 ± 
3.32, the “high” 8-OH-dG group consisted of 10 patients with an average baseline 8-OH-
dG level of 319.87 ± 103.56, and the “high” MDA group consisted of 10 patients with an 
average baseline MDA score of 4.23 ± 0.30. The patients in each group were ranked in 
order of highest to lowest and patients with multiple rankings in these “high” categories 
were identified to describe any correlation between VAS, OLP, 8-OH-dG, and MDA. 
Relationships between variables 
 The patient with the highest VAS (100) at baseline had the 2nd highest OLP 
score (16), but only 2 other patients in the top VAS grouping were also among the top 10 
Figure 9. Drop-out in the AO group at (A) baseline and (B) 2 weeks. Marked improvement in the gingival 
lesions were noted. 
A B 
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OLP lesion scores. In fact, the patient with the highest OLP lesion score (20.5) had a 
baseline VAS of 15. In addition, only 3 of the 8 “high” VAS patients were among the 10 
“high” 8-OH-dG patients. The patient with the highest VAS patient (100) had a baseline 
8-OH-dG level of 147.233 pg/ml which was below the overall average of 179.008 ± 
99.470 pg/ml. As for VAS and MDA, 4 of the 8 high VAS patients were among the 10 
“high” MDA patients. The patient with the highest VAS (100) had an MDA level of 
3.586 μM which was only slightly above the overall average of 3.385 ± 0.789 μM. When 
examining if an increase in 8-OH-dG and MDA levels from baseline to 4 weeks 
corresponded with an increase in VAS, the results showed 7 patients in the PLC and 4 in 
the AO group had an increase in 8-OH-dG at 4 weeks compared to baseline, and 8 
patients in the PLC group and 12 in the AO group had an increased MDA at 4 weeks. 
However, none of these patients had a corresponding increase in VAS from baseline to 4 
weeks.  
For OLP scores, only 1 of the 10 “high” OLP score patients were among the 10 
“high” 8-OH-dG patients. In fact, the patient with the highest OLP score at baseline 
(20.5) had an 8-OH-dG level of 156.882 pg/ml which was below the overall average of 
179.008 ± 99.470 pg/ml. Also, 4 of the patients with the 10 highest OLP lesions scores 
were among the 10 “high” MDA patients. The patient with the highest OLP score at 
baseline (20.5) had a baseline MDA level of 3.586 μM which was only slightly above 
the overall average of 3.385 ± 0.789 μM. When examining if an increase in 8-OH-dG 
and MDA levels corresponded to an increase in OLP scores, the results showed that 
none of the patients with increased 8-OH-dG at 4 weeks had a corresponding increase in 
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OLP score, and only 1 patient with an increase in MDA at 4 weeks had a corresponding 
increase in OLP score. 
In addition, only 3 of the 10 “high” 8-OH-dG patients ranked among the 10 high 
MDA patients. Table 6 shows the patients who were among the “high” group in each 
category. In total, 4 patients were among the “high” groups in 3 categories while most 
ranked in 2 or fewer categories (Table 6). 
OLP presentation 
A majority of patients presented with reticular lesions: 31 out of 33 patients 
presented with the reticular form of OLP (93.9%). Twenty-three patients presented with 
erythematous lesions (69.7%), and 8 patients presented with ulcerative lesions (24.24%). 
Of the 10 with no baseline erythematous lesions, 4 remained free of erythematous 
lesions but 6 (3 each in the AO and PLC groups) developed erythematous lesions at one 
point or another during the remainder of the study. Half of these patients had no 
erythematous at the final visit and of the 3 who did not have resolution of erythematous 
lesions at 4 weeks, 2 had an increase in both MDA and 8-OH-dG. No other relations 
could be explored in regards to patients with erythematous lesions versus those without 
since a majority of patients presented with erythematous lesions. 
As for ulcerative lesions, 5 of the 8 patients in the “high” VAS group had 
ulcerative lesions, 5 of 10 patients in the high OLP score group had ulcerative lesions, 4 
of 10 patients in the high 8-OH-dG group had ulcerative lesions, and 3 of 10 patients in 
the high MDA group had ulcerative lesions. 
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Table 6. Highest scores for each variable. This table represents the “high” patients categorized by 
variable and ranked from highest to lowest. The patient numbers coded with warm colors indicate 3 top 
ranks, cool colors represent 2 top ranks, and no color represents no additional top ranks. 
 
 
Lesion location 
 The breakdown of areas of involvement at baseline and percentages are presented 
in Table 7. Gingival lesions were the most prevalent in the study with 23 out of 33 
patients (69.7%) presenting with maxillary gingival lesions and 24 out of 33 patients 
(72.7%) presenting with mandibular gingival lesions. Only 5 patients (15.2%) had no 
gingival involvement. Three patients, all in the PLC group, developed gingival lesions at 
the time of the 4 week recall, but only 1 patient had a corresponding increase of MDA at 
4 weeks and none had a corresponding increase in 8-OH-dG at 4 weeks. The second 
most common location was on the buccal mucosa (60.6% for right and left buccal 
mucosa). The least prevalent locations in this population of patients were the floor of the 
mouth and the ventral tongue (3%). Out of all the areas of involvement, the buccal and 
labial mucosal sites had the highest incidence of remission. 2 out of the 3 initial patients 
Patient VAS Patient OLP score Patient 8-OH-dG Patient MDA 
1B 100 13B 20.5 12B 524.4485 13A 4.9105 
10A 90 1B 16.0 5A 444.656 18B 4.501 
5A 83 3B 13.0 19A 366.653 3B 4.4365 
2A 80 9A 12.5 2A 366.156 8A 4.186 
17B 76 17B 12.0 18B 307.679 10B 4.128 
4B 70 14A 11.5 10A 254.086 10A 4.1025 
3B 70 12A 11 14A 245.124 13B 4.100 
14B 57 2B 10.5 7B 244.9865 4B 4.062 
  4B 10.0 13A 230.1445 4A 3.9835 
  15B 9.5 6A 214.775 17B 3.911 
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with upper/labial mucosal lesions had complete remission by 4 weeks and 3 out of the 20 
patients with right buccal mucosal lesions and 3 out of the 20 patients with left buccal 
mucosal lesions achieved complete remission by 4 weeks. Only 1 patient with 
mandibular gingival lesions achieved complete remission of that site by 4 weeks (Table 
7). 
 
 
Table 7. Summary of lesion locations 
 
 
Effects of adjunctive therapy 
As part of the protocol, patients were allowed to use their current therapy for 
OLP in addition to either the placebo or active formula. However, at various time points 
in the study, a total of 17 patients (8 in the PLC group, 9 in the AO group) had decided 
on their own accord to quit using their current therapy and use only the placebo/active 
gel. To investigate if the concurrent use of other therapies, or absence of it, affected the 
Lesion location 
No. patients 
Baseline 
% patients 
Baseline 
No. patients 
4 Weeks 
% patients 
4 Weeks 
Upper/lower labial mucosa 3 9.1 1 3.0 
Right buccal mucosa 20 60.6 17 51.5 
Left buccal mucosa 20 60.6 17 51.5 
Hard palate 2 6.1 2 6.1 
Dorsum of tongue 2 6.1 2 6.1 
Ventral tongue 1 3.0 1 3.0 
Floor of mouth 1 3.0 1 3.0 
Maxillary gingiva 23 69.7 23 69.7 
Mandibular gingiva 24 72.7 23 69.7 
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results, patients were stratified into four groups: 1) a placebo only group (PLC Only), 2) 
an active only group (AO Only), 3) a placebo plus their current therapy group 
(PLC+TX), or 4) an active plus current therapy group (AO+TX). Statistical analysis was 
completed to examine for any within group differences at each time point for each 
variable, and to examine for any differences among the 4 groups at each time point for 
each variable. Table 8 shows the result of analyses which revealed that asides from the 
significant difference in baseline VAS and OLP score between the PLC Only and 
PLC+TX group, there were no differences at any time point between any of the 4 groups 
for any of the variables. 
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Table 8. Effects of use of topical steroids; † - P <0.05 between PLC Only and PLC+TX groups 
VAS PLC Only 
(n = 8) 
AO Only 
(n = 9) 
PLC+TX 
(n = 7) 
AO+TX 
(n = 6) 
P values 
Baseline 12.63 ± 11.33† 33.25 ± 28.82 49.00 ± 32.89† 50.67 ± 36.13 >0.05 
2 Weeks 7.13 ± 8.17 14.25 ± 14.05 37.86 ± 28.12 20.50 ± 18.41 >0.05 
4 Weeks 13.75 ± 9.18 16.75 ± 22.14 30.00 ± 27.87 23.67 ± 34.33 >0.05 
P values >0.017 >0.017 >0.017 >0.017  
OLP lesion score      
Baseline 5.44 ± 3.10† 7.79 ± 5.18 11.43 ± 5.82† 7.08 ± 4.83 >0.05 
2 Weeks 4.63 ± 3.64 6.26 ± 4.10 8.50 ± 4.37 5.75 ± 4.22 >0.05 
4 Weeks 4.44 ± 3.67 6.53 ± 4.63 8.57 ± 5.05 5.83 ± 3.47 >0.05 
P values >0.017 >0.017 >0.017 >0.017  
8-OH-dG (pg/ml)      
Baseline 170.17 ± 79.72 216.88 ± 132.01 162.83 ± 108.95 193.48 ± 138.05 >0.05 
4 Weeks 183.81 ± 152.36 178 ± 116.56 212.78 ± 179.78 141.62 ± 80.12 >0.05 
P values >0.017 >0.017 >0.017 >0.017  
MDA (µM)      
Baseline 3.52 ± 0.73 3.24 ± 1.07 3.34 ± 0.96 3.21 ± 0.88 >0.05 
4 Weeks 3.09 ± 0.93 4.63 ± 1.82 3.97 ± 1.40 5.03 ± 1.01 <0.05 
P values >0.017 >0.017 >0.017 >0.017  
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DISCUSSION 
 
This was the first study to investigate the efficacy of a topical antioxidant 
combination gel in treating patients with OLP and also the first interventional study 
analyzing salivary biomarkers of oxidative stress before and after treatment. Alleviation 
of symptoms and clinical signs of the disease are important variables in determining the 
efficacy of any potential treatment for patients with chronic, often painful diseases such 
as OLP. VAS is usually the standard method to subjectively measure symptoms in 
patients. Chainani-Wu et al studied the efficacy of antioxidant curcuminoids to treat 
OLP in a randomized, placebo-controlled, double-blind clinical study. They found no 
difference between 12 patients receiving curcuminoid capsules and 16 patients taking the 
placebo in terms of VAS after 49 days112. Saawarn et al studied the efficacy of lycopene 
softgel capsules in a placebo-controlled clinical study. At 8 weeks, they found no 
difference in VAS scores between the 15 patients taking the lycopene capsules compared 
to the 15 patients in the placebo113. In our study, although there was a statistically 
significant reduction in VAS from baseline to 2 weeks for the PLC group and from 
baseline to 2 and 4 weeks for the AO group, there were no statistically significant 
differences between the two groups at any time point. Two other studies have looked at 
antioxidants given in capsule form as an intervention. Inherent bias exists in the VAS as 
patients were told to indicate with a single mark on a standardized 10 cm line which best 
represented their current symptoms. In our study, having “symptoms” was defined as 
having any unpleasant sensation such as, but not limited to, pain, discomfort, soreness, 
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and burning sensations. To facilitate uniformity, patients were instructed to evaluate 
their symptoms that day, and for the 2 week and 4 week follow-ups, they were told to 
view the VAS from their previous visits as reference. Despite this, wide variability was 
noted in the responses. The error inherent in the VAS is well documented115, 116 and it 
was no surprise that the only subjective measure in this study was perhaps the weakest. 
The measure for clinical efficacy was the lesion scoring. Statistically significant 
reductions in OLP lesion score was observed from baseline to 2 weeks in the PLC group 
and from baseline to 4 weeks in the AO group. Again, as with the VAS, no differences 
were found between the two groups at any time point. This was similar to the study by 
Chainani-Wu et al in that there were no difference between the active and placebo 
groups in terms of lesion scoring112. Saawarn et al recorded clinical response using the 
Tel Aviv-San Francisco scale and found that at 4 weeks through 8 weeks, the score for 
clinical response in the lycopene group was statistically better than the response in the 
placebo group113. A possible reason for a lack of statistically significant differences 
between the two groups in this study may be related to the scoring system used. 
Although the overall score is reported and analyzed as interval data, the subset scores are 
ordinal. Erythematous and ulcerative lesions are graded based on lesion area: 0 = no 
lesion, 1 = lesion present but ≤1 cm2, 2 = lesion >1 cm2 but ≤3 cm2, and 3 = lesion >3 
cm2. The area difference between a score of 1 and 2 is 2 cm2, which is twice the interval 
between a score of 0 and 1. Some lesions, which were scored a 2 on initial examination, 
actually showed regression in size (Fig. 7, A-C), but if the regression in size was not 
large enough, the lesion would have still been scored a 2. Obviously, the score would not 
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reflect more subtle, but noticeable, clinical changes. Indeed, clinical observations and 
retrospective analysis of photographs suggest there was some improvement in most 
cases in the AO group, particularly in regards to the intensity of the erythematous 
lesions. Unfortunately, the scoring system used does not account for changes in intensity 
of erythematous lesions. We attempted retrospective analysis of erythematous lesions 
using an erythema index117, but due to different angulation and lighting conditions of the 
photographs, we were unsuccessful at our attempt. Regardless, several lesions in the AO 
group did seem to pass the “eye test” in terms of subtle improvement. Only one group of 
investigators have used this scoring system to analyze post-treatment oral lesion size. 
Cutler et al found no significant difference between baseline and 1 year oral lesion 
scores and they only briefly mention that perhaps their “clinical measurement tools were 
inadequate to detect improvement118.” Retrospectively, perhaps supplementing the 
scoring system by Pibooniyom et al114 with one in which the transition from one lesion 
score to another was linear and better able to detect smaller, but visually noticeable 
changes, may have been beneficial. 
This is the second study to evaluate levels of salivary MDA in OLP patients and 
the first to do so after treatment. MDA is the main byproduct of lipid peroxidation by 
free radical interaction with cellular membranes. This study found a total average level 
of 3.69 μM ± 1.43 in all patients. Ergun et al reported MDA levels of 2.03 ± 0.81 
nmol/ml (μM) in the saliva of 21 untreated OLP patients compared to 1.37 ± 0.37 μM in 
the saliva of 20 healthy controls108. Other studies reported on serum levels of MDA. 
Sezer et al reported 18.24 μM ± 5.21 in untreated OLP patients compared to 15.66 ± 
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5.23 μM in healthy controls, Aly & Shahin reported 18.09 μM ± 3.02 compared to 15.46 
± 3.32 μM in healthy controls, and Upadhyay et al reported 0.7595 μM ± 0.536 
compared to 0.2187 ± 0.054 μM in healthy controls104, 106, 107.  The salivary MDA levels 
observed in this study are similar in range to that of the OLP patients and higher than the 
controls observed by Ergun et al108. Most previous studies measured MDA levels in 
serum whereas this study looked at salivary levels which are appropriate in the context 
of studying free radical damage to cell membrane of the keratinocytes in the local 
environment of the oral cavity. It was a peculiar observation that MDA levels actually 
increased to a statistically significant level after 4 weeks of usage of the active 
formulation. Additional investigation found the MDA increase was not associated with 
any of the other clinical parameters such as lesion type and lesion location, and these 
changes appeared to be opposite of direction of the VAS and OLP lesion scores from 
baseline to 4 weeks. A reasonable explanation for this observation is elusive at this time 
but a small sample size makes it difficult to predict whether or not this would be true in a 
larger sample.  
To the best of our knowledge, this is the first study to examine the level of 
salivary 8-OH-dG as a marker of oxidative stress in oral lichen planus patients. 8-OH-
dG is a by-product of DNA damage by free radicals and has been found to be much 
higher in patients with chronic periodontitis. Dede et al used the same commercially 
available kit for salivary analysis of 8-OH-dG in patients with chronic periodontitis. 
They found patients with chronic periodontitis had 605.5 pg/ml ± 139.1 and healthy 
patients had 550.52 pg/ml ± 150.28119. Takane et al used a different method of 
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immunoassay and observed an average level of 3.29 ng/ml ± 0.21 in the saliva of chronic 
periodontitis patients before treatment compared to 1.56 ± 0.10 ng/ml in healthy 
patients120. In this study, the average level of salivary 8-OH-dG for all patients at 
baseline was 197.37 ± 115.42 pg/ml or 0.197 ± 0.115 ng/ml. We observed lower levels 
of 8-OH-dG in our study population compared to both diseased and healthy patients in 
these other studies. However, chronic periodontitis may have different oxidative stress-
mediated mechanisms for tissue destruction and disease progression than that of OLP, 
and this may have accounted for the differences. Regardless, our data showed that there 
was no statistically significant differences between the groups in the salivary levels of 8-
OH-dG from baseline to 4 weeks. This finding appeared to be related to the lack of 
statistically significant differences in VAS and OLP. Also, the levels of salivary 8-OH-
dG did not appear to be correlated to changes in VAS or OLP. None of the patients who 
had an increase in 8-OH-dG at 4 weeks from baseline had a higher VAS nor OLP score 
at 4 weeks from baseline. In addition, only 3 patients with the top 10 highest 8-OH-dG 
levels also ranked in the top 10 for MDA levels. Based on these observations, despite an 
almost 18% decrease in levels of 8-OH-dG in the AO group, 8-OH-dG did not appear in 
this study to be associated strongly with any clinical features of OLP. This finding is 
rather disappointing when trying to contribute to the scarce literature linking 8-OH-dG 
and oxidative stress to OLP. Another confounding factor in this study may have been 
that levels of 8-OH-dG may have been from periodontal disease found in some of our 
patients. The presence of periodontitis was not an exclusion criteria in this study, and the 
previous cited studies, Dede et al and Takane et al, have shown that salivary levels of 8-
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OH-dG are undoubtedly higher in patients with periodontitis than healthy controls119, 120. 
Coupled with the lack of significant change in MDA levels, it appears that the use of this 
regimen of the antioxidant gel may not result in a statistically significant change in the 
patients’ levels of either of these oxidative stress markers. 
Several reasons may account for the lack of statistical difference in all 
parameters studied excluding the increased salivary MDA at 4 weeks in the AO group. 
First, the number and characteristics of the patients in the study may not have been ideal. 
Recruitment was difficult in that many patients were asymptomatic and were not willing 
to participate. Reasons for weak recruitment include the lack of transportation, inability 
to contact, and driving distances. Even within the study population, some parameters 
were not ideal at baseline. For example, numerous patients had a VAS less than 20 (12 
total). Given that the literature has shown variation of 20% on a repeated VAS115, 
inclusion of the data sets which had a baseline VAS of less than 20 may have masked 
effects of the test gel since these patients limited their future responses to staying the 
same or increasing the VAS. Also, the majority of the patients had reticular lesions 
either alone or in combination with erythematous and ulcerative forms. The literature has 
shown a majority of patients with reticular lesions are asymptomatic. Since nearly all 
(94%) of patients in this study presented with reticular lesions, and some with reticular 
lesions alone, it would be expected that the VAS may tend to be skewed towards the low 
end. In this study, patients who presented with ulcerative lesions, which the scoring 
system presumes to be the most painful, tended to have higher VAS, much like what the 
literature reports38. However, many of the patients with higher OLP scores did not 
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necessarily have the highest VAS scores at baseline. A possible reason is that many of 
the patients in the study had been in long term management (> 12 months) of their OLP 
and had reached a level of acceptance. Second, the placebo may have had some inherent 
antioxidant properties. Although no ferulic acid or phloretin was utilized in the placebo, 
secondary ingredients include menthol, peppermint oil, thyme, sage oil, clove flower oil, 
and xylitol. The literature has shown that all of these secondary ingredients do have 
some level of antioxidant function121-124. It may not have been feasible to provide a 
placebo in the same consistency, color, taste, and smell as the test without the use of the 
ingredients. However, since all of these secondary ingredients are found in both the 
placebo and the test, it would be assumed that any differences would be attributed to 
phloretin and ferulic acid only. 
Another possible reason for the lack of difference between the AO and PLC 
groups may be attributed to the area of involvement in the patients. Most patients had 
gingival lesions either on the maxilla (69.7%) or mandible (72.7%). This is higher than 
what the classic literature reports6, 8, 9. Gingival lesions did provide a unique set of 
challenges in the measurement of the OLP score. We found reticular and ulcerative 
scores to be easily measured if found on the gingiva, but erythematous scores were 
difficult for several reasons. Involvement of papillae made measuring with a calibrated 
polygon on transparency paper difficult to do. Perhaps adjunctive use of a grid method 
used by Plemons et al would have been beneficial54. Another interesting finding is that 
only 1 patient had remission of their gingival lesions at 4 weeks while more patients with 
labial or buccal mucosal lesions were able to achieve complete remission. This finding 
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that most gingival lesions in this study failed to achieve remission may be attributed to 
an inability of the scoring system to identify qualitative changes in erythema in the 
gingiva. This is an important fact since most of the gingival lesions present in this study 
were erythematous lesions. Also, as mentioned above, patients were not excluded for 
periodontitis, and it is possible that some of the lack of recorded improvement may have 
been from overlying plaque-induced gingival inflammation. Other than these issues, 
observations of the trends associated with lesion location did not reveal any relationship 
between the intensity of the VAS and OLP score nor did the location affect either levels 
of salivary biomarkers. 
Some weaknesses of the study include small samples size, study duration, 
incomplete data for salivary MDA at 4 weeks, and wide variability in the clinical 
parameters and their associated measuring instruments. Also, some ambiguity may have 
existed in demonstration and instruction for use. One patient was not compliant at all and 
was dismissed from the study. The patients were instructed not to eat or drink for 30 
minutes after each use, but instruction was not given on how long the patients should 
wait before spitting the excess amounts out. The time that the gel is left within the mouth 
before being expectorated may have potentially been a confounder in this study. Also, 
despite informing patients they were to continue their current therapy concurrently with 
the use of either the placebo or active gel, a large number of patients (17 total) had 
decided to stop use of their current therapy. This decision was made on the patient’s own 
accord. Although this may have been a confounder, analysis showed that whether or not 
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patients used another therapy at the same time during the study probably did not have 
any effect on the final results (Table 8). 
Despite the absence of differences in VAS, OLP score, and salivary 8-OH-dG 
and MDA levels from baseline to completion of the study between the placebo and test 
group, there are some findings which support further investigation of the use of 
combination antioxidants in the treatment of OLP. Although the study duration was only 
4 weeks, the fact that none of the patients reported flare-ups associated with OLP signs 
and symptoms during use of either the test or placebo suggest that the combination 
antioxidant gel as a maintenance treatment may be warranted. This would be helpful to 
patients whom the bad taste of topical steroids tend to limit compliance. It is worth 
noting that 2 patients (1 in each group) developed candidiasis-like signs and symptoms 
such as pseudomembranous lesions and burning sensations. Candidiasis was confirmed 
with a salivary candida culture. Both patients had reported a previous history of frequent 
bouts of candidiasis and both had used clobetasol during the duration of the study. It 
would be of interest to investigate the frequency of oral candidiasis in susceptible 
patients using a combination antioxidant rather than topical steroids. Furthermore, 
although not statistically significant, the trend towards more reduction in the VAS, OLP, 
and 8-OH-dG in the AO group suggests that a study with a longer duration and more 
intensive application regimen may result in significant clinical and statistical findings. 
Within the limits of this study, the use of a topical combination antioxidant gel in 
management of patients with persistent and non-responsive OLP was not statistically 
different from a placebo formulation in terms of reducing VAS, OLP score, and salivary 
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8-OH-dG and MDA levels. However, future investigation is warranted in evaluating the 
efficacy of a longer duration and perhaps a more intensive regimen on these clinical 
parameters. 
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CONCLUSIONS 
 
Within the limits of this study, the patients receiving the active AO gel had 
significant improvement in VAS throughout the 4 weeks and an improved OLP lesion 
score from baseline to 4 weeks. Patients receiving the AO gel had lower levels of 
salivary 8-OH-dG before than after treatment. Interestingly, MDA levels increased 
significantly at 4 weeks in the AO group, and this observation cannot currently be 
explained. Overall, the differences between the groups were not statistically significant 
at any point in time except for salivary MDA levels at 4 weeks. Despite the fact that 
there were limitations to this study such as a small sample size and large variability in 
the data, there may be a place clinically for the use of this topical combination 
antioxidant gel in the maintenance of patients with oral lichen planus who have not 
received further benefit from conventional topical therapy. Future research should 
further investigate the efficacy of longer use and perhaps a heavier dosage of 
antioxidants. 
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